



# CHEST<sup>®</sup> Physician

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS



HAZEMKAVAL/Getty Images

## CDC closing in on source of vaping-associated lung injuries

**BY THERESE BORDEN**

*MDedge News*

**T**he Centers for Disease Control and Prevention has announced a possible breakthrough in the hunt for the source of a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injuries (EVALI): vitamin E acetate found in lung fluid of victims.

In a telebriefing, Anne Schuchat, MD, the CDC's principal deputy director, provided an update on recent lab findings and on case and death numbers reported so far to the CDC. The findings and more case information were published in the Mortality and Morbidity Weekly Report.

At the telebriefing, Dr. Schuchat stated that CDC has received 29 samples of bronchoalveolar lavage (BAL) fluid from EVALI patients from 10 states and that vitamin E acetate was identified in all samples. Vitamin E acetate has already been found in some vaping devices and the discovery of the chemical in the lungs of patients increases the likelihood that this toxin is at least one source of EVALI. These findings are the first to link substances found in vaping products with biological samples from patients hospitalized with EVALI.

Tetrahydrocannabinol (THC) was found in 23 of 28 samples tested, and nicotine was found in 16 of 26 samples tested. Other diluents and addi-

**VAPING** // *continued on page 7*

## Cystic fibrosis breakthrough: Triple therapy effective for common mutation

**BY STEVE CIMINO**

*MDedge News*

**R**einforcing previous findings, a new study has determined that the next-generation corrector elxacaftor, in combination with tezacaftor and ivacaftor, can effectively treat patients with Phe508del-minimal function genotypes who did not respond to previous cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimens.

"These results provide evidence that elxacaftor-tezacaftor-ivacaftor can modulate a single Phe508del allele in people with cystic fibrosis, thus addressing the underlying cause of disease in the large majority of patients," wrote Peter G. Middleton, PhD, of the University of Sydney and his coauthors. The study was published in the *New England Journal of Medicine*.

To further determine if the elxacaftor-tezacaftor-ivacaftor regimen was effective and safe, the researchers launched a randomized, placebo-controlled phase 3 trial of 403 cystic

**CYSTIC FIBROSIS** // *continued on page 6*

### INSIDE HIGHLIGHT



#### NEWS FROM CHEST

**CHEST Foundation establishes Mark J. Rosen, MD, Master FCCP Endowment.**

*Page 31*



**SAVE THE DATE**

Chicago, Illinois | October 17-21

Presorted Standard  
U.S. Postage  
PAID  
Permit No. 384  
Lebanon Jct., KY

CHANGE SERVICE REQUESTED

**CHEST PHYSICIAN**  
10255 W Higgins Road,  
Suite 280  
Rosemont, IL 60018

# FDA noncommittal on e-cigarette action

BY GREGORY TWACHTMAN

*MDedge News*

**D**espite some strong words by the White House in September 2019 regarding action to help

curb the growing epidemic of youth vaping and e-cigarette use, a Food and Drug Administration official deflected questions on when the agency would act and what actions it was planning on taking.

“I was actually shocked that, in a hearing that is focused in part on the youth vaping epidemic [that] your testimony, both written and oral here, made no mention of the administration’s Sept. 11 announce-

ment that it intended to clear the market of all unauthorized non-tobacco-flavored vaping products,” said Sen. Patty Murray (D-Wash.), ranking member of the Senate Health, Education, Labor and Pen-

This advertisement is  
not available for the digital edition.

 **CHEST**<sup>™</sup> Physician  
THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

sions Committee, during a Nov. 13 hearing to Mitchell Zeller, director of the FDA's Center for Tobacco Products. "Why is that not included in your testimony?"

Director Zeller would only offer a vague response, testifying that the agency is "committed to doing everything that we can to prevent kids

from using any tobacco product, including e-cigarettes, and that we are continuing to develop a policy approach that aligns with that concern."

When Sen. Murray pressed further, Director Zeller deflected: "I think that any questions that the committee has about the announce-

ment that the White House and anything related to what remains a deliberative process on policy is best referred to the White House itself."

He would not even offer any perspective on when the FDA might take actual regulatory action when asked about it by Sen. Murray.

"I can't give you a specific time-

line, Senator, other than to say that the deliberative process continues," Director Zeller responded, telling her that "I really would refer you and the committee to the White House to ask specific questions about where we are."

The hearing, called to examine the response to lung illnesses and rising youth e-cigarette usage, shed no new light on the issue. And while Director Zeller outlined the numerous educational campaigns being aimed at convincing youth to not use e-cigarettes, Committee Chairman Lamar Alexander (R-Tenn.) questioned whether the FDA was doing an adequate job.

*Mitchell Zeller, director of the FDA's Center for Tobacco Products, deflected questions on when the agency would act on curbing e-cigarette use among youth, and said, "I really would refer you and the committee to the White House to ask specific questions about where we are."*

This advertisement is  
not available for the digital edition.

 **CHEST**™ Physician  
THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

The FDA, from late 2017 to the end of 2020, "will wind up investing about \$150 million in a massive, multimedia public education campaign to get the word out to kids" on the dangers of vaping, Director Zeller said, adding that the agency is "aggressively enforcing" youth access restrictions in targeting sellers of e-cigarette products to minors.


"Well, obviously we are not making much progress with youth use ... if one in four of American high schoolers, according to your statistics, are using e-cigarettes," Sen. Alexander said.

While most on the committee were focused on the rising numbers of youth vaping and e-cigarette usage, Sen. Rand Paul (R-Ky.) cautioned that any regulatory action, particularly a ban on all flavored e-cigarette products, would adversely affect adults, particularly those who are turning to e-cigarettes as a smoking cessation tool.

His solution, noting that it is already illegal for kids to be purchasing vaping and e-cigarette products, was to increase the penalties for those found selling to minors, adding that "most adults are using the flavors as well" and it could lead them back to combustible tobacco products if they are prevented from accessing flavored e-cigarettes.

gtwachtman@mdedge.com



CHEST PHYSICIAN  
IS ONLINECHEST Physician is available at  
[chestphysician.org](http://chestphysician.org).

David A. Schulman, MD, FCCP, is Medical Editor in Chief of CHEST Physician.

## Cystic fibrosis symptoms improved // continued from page 1

fibrosis patients age 12 or older who had a single Phe508del allele. Patients in the combination group (n = 200) received 200 mg of elexacaftor once daily, 100 mg of tezacaftor once daily, and 150 mg of ivacaftor every 12 hours for 24 weeks. Patients in the other group (n = 203) received matched placebos.

At 14 weeks, patients in the combination group had a change in percentage of predicted forced expiratory volume in 1 second (FEV<sub>1</sub>) that was 13.8 points higher than the placebo group (95% confidence interval, 12.1-15.4; P less than .001).

At 24 weeks, the combination group had a predicted FEV<sub>1</sub> difference that was 14.3 percentage points higher (95% confidence interval, 12.7-15.8, P less than .001). The rate of pulmonary exacerbations was 63% lower (rate ratio, 0.37; 95% CI, 0.25-0.55; P less than .001) and sweat chloride concentra-

tion was 41.8 mmol/L lower (95% CI, -44.4 to -39.3; P less than .001) in the combination group through 24 weeks.

At least one adverse event occurred in 93.1% of patients in the combination group and 96% of patients in the placebo group. Serious adverse events occurred in 28 patients (13.9%) in the combination group and 42 patients (20.9%) in the placebo group. There were no deaths in either group.

The study was funded by Vertex Pharmaceuticals. The authors had disclosures, including receiving personal fees and grants from various pharmaceutical companies and being on the advisory board, owning stock, or being an employee of Vertex Pharmaceuticals.

[chestphysiciannews@chestnet.org](mailto:chestphysiciannews@chestnet.org)

**SOURCE:** Middleton PG et al. 2019 Oct 31. *N Engl J Med*. doi: 10.1056/NEJMoa1908639.

## VIEW ON THE NEWS

## The dream of targeted therapies for cystic fibrosis may now be reality

After 30 years, new research from Middleton et al. and others appears to be the breakthrough we've been waiting for in treating cystic fibrosis, wrote Francis S. Collins, MD, PhD, of the National Institutes of Health in an accompanying editorial (*N Engl J Med*. 2019 Oct 31. doi: 10.1056/NEJMe1911602).

As one of the researchers who discovered the cystic fibrosis gene, he acknowledged the 3 decades of work that followed their discovery and the excitement that comes from being able to counter the common Phe508del CFTR mutation that afflicts so many cystic fibrosis patients. "These findings indicate that it may soon be possible to offer safe and effective molecularly targeted therapies to 90% of persons with cystic fibrosis," he wrote.

"Yet we must not abandon the patients with cystic fibrosis who have null mutations and will not have a response to these drugs," he added, noting that those challenges remain "substantial" and potentially will involve in vivo somatic-cell gene editing of airway epithelial cells. That said, what once was a dream 30 years ago now appears to be a reality.

*Dr. Collins reported being a coinventor of the original patents on the CFTR gene, for which he donated all royalties to the Cystic Fibrosis Foundation.*

INNOVATIVE  
MEDICINE

## Best Practices

Treatment of Unresectable Stage III  
Non-small Cell Lung Cancer

By M. Patricia Rivera, MD, FCCP

This article is sponsored by AstraZeneca | page 8

Available at: [MDedge.com/ChestPhysician](http://MDedge.com/ChestPhysician)

US-33194

Last Updated 9/19

CHEST<sup>®</sup> Physician

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

AMERICAN COLLEGE OF CHEST  
PHYSICIANS (CHEST)

## EDITOR IN CHIEF

David A. Schulman, MD, FCCP

## PRESIDENT

Stephanie M. Levine, MD, FCCP

## EXECUTIVE VICE PRESIDENT &amp; CEO

Robert Musacchio

PUBLISHER, CHEST<sup>®</sup> JOURNAL

Nicki Augustyn

## MANAGER, EDITORIAL RESOURCES

Pamela L. Goorsky

## PUBS &amp; DIGITAL CONTENT EDITOR

Martha Zaborowski

## SECTION EDITORS

Corey Kershaw, MD

*Pulmonary Perspectives<sup>®</sup>*

Angel Coz, MD, FCCP

*Critical Care Commentary*

Michelle Cao, DO, FCCP

*Sleep Strategies*

## EDITORIAL ADVISORY BOARD

G. Hossein Almassi, MD, FCCP, *Wisconsin*Jennifer Cox, MD, FCCP, *Florida*Jacques-Pierre Fontaine, MD, FCCP, *Florida*Eric Gartman, MD, FCCP, *Rhode Island*Octavian C. Ioachimescu, MD, PhD, FCCP, *Georgia*Jason Lazar, MD, FCCP, *New York*Susan Millard, MD, FCCP, *Michigan*Michael E. Nelson, MD, FCCP, *Kansas*Daniel Ouellette, MD, FCCP, *Michigan*Frank Podbielski, MD, FCCP, *Massachusetts*M. Patricia Rivera, MD, FCCP, *North Carolina*Nirmal S. Sharma, MD, *California*Krishna Sundar, MD, FCCP, *Utah*E-mail: [chestphysiciannews@chestnet.org](mailto:chestphysiciannews@chestnet.org)FRONTLINE  
MEDICAL COMMUNICATIONSFRONTLINE MEDICAL  
COMMUNICATIONS  
SOCIETY PARTNERS

## VP/GROUP PUBLISHER; DIRECTOR,

FMC SOCIETY PARTNERS Mark Branca

EXECUTIVE EDITORS Denise Fulton, Kathy

Scarbeck

EDITOR Therese Borden

CREATIVE DIRECTOR Louise A. Koenig

DIRECTOR, PRODUCTION/MANUFACTURING

Rebecca Slebodnik

DIRECTOR, BUSINESS DEVELOPMENT

Monique Michowski,

973-206-8015, cell 732-278-4549,

[mmichowski@mdedge.com](mailto:mmichowski@mdedge.com)

DIGITAL ACCOUNT MANAGER

Rey Valdivia 973-206-8094

[rvaldivia@mdedge.com](mailto:rvaldivia@mdedge.com)

CLASSIFIED SALES REPRESENTATIVE

Drew Endy 215-657-2319,

cell 267-481-0133

[dendy@mdedge.com](mailto:dendy@mdedge.com)

SENIOR DIRECTOR OF CLASSIFIED SALES

Tim LaPella, 484-921-5001,

[tlapella@mdedge.com](mailto:tlapella@mdedge.com)

**CHEST PHYSICIAN**, the newspaper of the American College of Chest Physicians, provides cutting-edge reports from clinical meetings, FDA coverage, clinical trial results, expert commentary, and reporting on the business and politics of chest medicine. Each issue also provides material exclusive to CHEST members. Content for **CHEST PHYSICIAN** is provided by Frontline Medical Communications Inc. Content for News From Chest is provided by the American College of Chest Physicians. The statements and opinions expressed in **CHEST PHYSICIAN** do not necessarily reflect those of the American College of Chest Physicians, or of its officers, regents, members, and employees, or those of the Publisher. The American College of Chest Physicians, its officers, regents, members, and employees, and Frontline Medical Communications Inc. do not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to products, drugs, or services mentioned herein.

**POSTMASTER:** Send change of address (with old mailing label) to CHEST PHYSICIAN, Subscription Services, 10255 W Higgins Road, Suite 280, Rosemont, IL 60018-9914.

**RECIPIENT:** To change your address, contact Subscription Services at 1-800-430-5450. For paid subscriptions, single issue purchases, and missing issue claims, call Customer Service at 1-833-836-2705 or e-mail [custsvcs.chph@fulcoinc.com](mailto:custsvcs.chph@fulcoinc.com)

**CHEST PHYSICIAN** (ISSN 1558-6200) is published monthly for the American College of Chest Physicians by Frontline Medical Communications Inc., 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609. Subscription price is \$244.00 per year. Phone 973-206-3434, fax 973-206-9378.

**EDITORIAL OFFICES** 2275 Research Blvd, Suite 400, Rockville, MD 20850, 240-221-2400, fax 240-221-2548

**ADVERTISING OFFICES** 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609 973-206-3434, fax 973-206-9378

©Copyright 2019, by the American College of Chest Physicians

## FRONTLINE MEDICAL COMMUNICATIONS

## Corporate

SVP, FINANCE Steven J. Resnick

VP, OPERATIONS Jim Chicca

VP, SALES Mike Guire

VP, SOCIETY PARTNERS Mark Branca

VP, EDITORIAL DIRECTOR, CLINICAL CONTENT

Karen Clemmens

VP, DIGITAL CONTENT &amp; STRATEGY Amy Pfeiffer

PRESIDENT, CUSTOM SOLUTIONS JoAnn Wahl

VP, CUSTOM SOLUTIONS Wendy Raupers

VP, HUMAN RESOURCES &amp; FACILITY OPERATIONS

Carolyn Caccavelli

DATA MANAGEMENT DIRECTOR Mike Fritz

CIRCULATION DIRECTOR Jared Sonners

CORPORATE DIRECTOR, RESEARCH &amp; COMMS.

Lori Raskin

DIRECTOR, CUSTOM PROGRAMS Patrick

Finnegan

In affiliation with Global Academy for Medical Education, LLC

PRESIDENT David J. Small, MBA

# Vaping-injury patient received double-lung transplant

BY GREGORY TWACHTMAN

*MDedge News*

**A** Michigan teenager, described as an athlete and otherwise healthy, has survived a double-lung transplant following lung damage attributed to vaping.

“On the 15th of October, the transplant team performed what we believe is the first double-lung transplant done in the nation for a vaping-injury victim, who is a teenager,” Hassan Nemeh, MD, cardiothoracic surgeon with the Henry Ford Health System in Detroit, said during a Nov. 12, 2019, press conference to discuss the surgery.


“What I saw in his lungs is nothing that I have ever seen before, and I have been doing lung transplants for 20 years,” Dr. Nemeh said. “There was an enormous amount of inflammation and scarring, in addition to multiple spots of dead tissue. The lung itself was so firm and scarred, we had to deliver it out of the chest. This is an evil that I haven’t faced before.”

He noted that the patient, now 17 years old but 16 when the surgical procedure occurred, is doing well in his recovery, and although the patient and the family are not yet ready to be identified, the health system made the decision to tell the story of the surgery as a cautionary tale.

“The reason we wanted to bring this case to public attention is because of the epidemic of e-cigarettes and vaping-induced lung injury that we are witnessing in the country,” including more than 2,000 cases of injury and 39 deaths that have been confirmed from lung failure related to e-cigarettes

and vaping that have been reported to the Centers for Disease Control and Prevention, he said.

“Our teenage patient would have faced certain death if it weren’t for the lung transplant happen-



**A CT scan of the lungs of the patient with severe lung damage shows a very limited area of ventilation before his double-lung transplant.**

ing,” Dr. Nemeh said, adding that, while vaping and e-cigarettes are being presented as a benign habit, there are potentially very deadly consequences that Henry Ford Hospital System wanted to highlight. He described the patient’s lungs as essentially being nonfunctional with very little air being able to be passed into them, with the de-

struction to his native lung from pneumonia and dead tissue almost completely covering his lungs.

This story began with a morning call on Oct. 1 from the Children’s Hospital of Michigan alerting the Henry Ford Health System that they had a patient on life support because of complete lung failure who was not showing signs of healing and asking if the Henry Ford Health System could possibly handle a lung transplant for this patient.

Dr. Nemeh said that the patient was on a non-transportable extracorporeal membrane oxygenation (ECMO) machine at Children’s. Dr. Nemeh and the team at Henry Ford determined that the situation for the patient was so dire that they put a portable ECMO machine into the trunk of Dr. Nemeh’s car and delivered it to Children’s in order to facilitate the transfer of the patient for transplantation surgery.

Victor Coba, MD, a critical care specialist and medical director of the ECMO program at Henry Ford, said: “We evaluated the irreversible lung damage that had occurred associated with vaping. Working closely with the lung transplant team and noting that his lungs would not recover, we worked to get him on the lung transplant list.”

“We are here today to beg the public to pay special attention to the steps that were taken in this case,” said Nicholas Yeldo, MD, anesthesiology and critical care specialist with Henry Ford. “Without the heroic measures that were taken in this case, this young patient would have died. There is no doubt about it.”

gtwachtman@mdedge.com

## Vitamin E acetate and THC are common factors in vaping illness // continued from page 1

tives of concern (such as plant oils, medium-chain triglyceride oil, petroleum distillates, and diluent terpenes) were not detected in BAL fluid specimens from EVALI patients.

BAL fluid specimens were collected from hospitalized EVALI patients in the course of their treatment, although not for the specific purpose of the CDC investigation, and sent to the CDC by public health laboratories and health departments in California, Connecticut, Hawaii, Illinois, Maryland, Michigan, Minnesota, Texas, Utah, and Wisconsin for analysis.

Dr. Schuchat stated that, as of Nov. 5, there have been 2,051 cases of EVALI reported to the CDC and 39 EVALI patients have died, with other deaths still under investigation as possibly related to EVALI. She said that the trend in new EVALI cases reported appears to be decreasing, but some states continue to see new cases. She cautioned that the lab findings of vitamin E acetate in BAL fluid do not rule out other possible compounds or ingredients that may contribute to EVALI and said the investigation will continue.

### E-cigarette user survey

During the telebriefing, Jennifer Layden, MD, PhD, chief medical officer and state epidemiologist with the Illinois Department of Public Health (IDPH), gave an update on her department’s efforts to investigate vaping behaviors that might have led to EVALI in e-cigarette users and also to obtain more information on sources of vaping devices that could be linked to EVALI. The data were also reported in a MMWR.

The IDPH conducted an online public survey during September 2019 and October 2019 targeting e-cigarette, or vaping, product users in Illinois. The survey was promoted via social media on the IDPH website, local health departments, and other outlets. The survey yielded 4,631 respondents who answered questions about the frequency of vaping, sources of supply, and types of substances used. The investigators were then able to compare vaping-use habits and behaviors with similar information gleaned from EVALI patients.

Among survey respondents, 94% reported using any nicotine-containing e-cigarette, or vaping, products in the past 3 months; 21% used any THC-containing products; and 11% used both THC-containing products and nicotine-containing products. THC-containing product use was highest among survey respondents aged 18-24 years (36%) and decreased with increasing age. Compared with these survey respondents, EVALI patients were more likely to report exclusive use of THC-containing products (adjusted odds ratio, 2.0; 95% confidence interval, 1.1-3.6), frequent use (more than five times per day) of these products (aOR, 3.1; 95% CI, 1.6-6.0), and obtaining these products from informal sources, such as from a dealer, off the street, or from a friend (aOR, 9.2; 95% CI, 2.2-39.4). In addition, “the odds of using Dank Vapes, a class of largely counterfeit THC-containing products, was also higher among EVALI patients” (aOR, 8.5; 95% CI, 3.8-19.0), according to the MMWR.

### Recommendations

CDC recommends that people should not buy any type of e-cigarette, or vaping, products, particularly those containing THC, off the street. They should also refrain from modifying or adding any substances to e-cigarette, or vaping, products that are not intended by the manufacturer, including products purchased through retail establishments.

Dr. Layden concluded, “we are in a better place today than we were a few weeks ago in terms of having one very strong culprit of concern based on the lung fluid testing,” but since the specific substances causing lung injury are not yet known, the only way to ensure that individuals are not at risk while the investigation continues is to consider refraining from use of all vaping products.

For more information and resources, visit For the Public, For Healthcare Providers, and For Health Departments pages, as well as the CDC’s Publications and Resources page.

tborden@mdedge.com



# INNOVATIVE MEDICINE

## Best Practices

### Treatment of Unresectable Stage III Non-small Cell Lung Cancer



#### M. Patricia Rivera, MD, FCCP

Professor of Medicine  
Division of Pulmonary and Critical Care  
Medicine  
Co-Director, Multidisciplinary Thoracic  
Oncology Program  
Director, Multidisciplinary Lung Cancer  
Screening Program  
Medical Director, Bronchoscopy and PFT  
Laboratory  
University of North Carolina at Chapel  
Hill  
Chapel Hill, NC

#### Introduction

With a recent renaissance in cancer diagnostics and treatment, there is renewed promise for many who previously held little hope. Lung cancer represents the second most frequently diagnosed cancer, a close second to breast cancer, at 12.9% of expected new cancer cases in 2019.<sup>1</sup> However, the 23.5% death rate predicted for lung cancer outranks breast, prostate, colorectal, and skin melanomas combined.<sup>1</sup> Five-year lung cancer survival rates have increased from 11% in 1975 to more than 20% in 2016.<sup>1</sup> This relatively low rate of survival can probably be explained by the fact that the majority of patients are diagnosed with locally advanced disease (Stage III, disease metastatic to mediastinal or supraclavicular nodes) or advanced disease (Stage IV, disease metastatic to other organs).<sup>2-4</sup> Recent advancements in treatment are proving effective in improving patient outcomes<sup>5,6</sup>; combined with adherence to screening recommendations and immediate referral to appropriate specialists, earlier diagnosis and staging can help lead to improved outcomes.<sup>7-9</sup>

Non-small cell lung cancer (NSCLC) constitutes 80% to 85% of lung cancer diagnoses, including histological identification of adenocarcinoma, squamous cell, large cell, and undifferentiated carcinomas.<sup>10-12</sup> Approximately 25% to 30% of patients with NSCLC are diagnosed with locally advanced or Stage III disease.<sup>12</sup> A proportion of these patients may experience the curative benefits of combined chemotherapy and surgery or concurrent chemotherapy and radiation therapy.<sup>5,13</sup> About 40% of patients with NSCLC are diagnosed with Stage IV disease, and the treatment goal in these patients is to manage symptoms, improve quality of life, and extend survival.<sup>13,14</sup> Treatment options include systemic chemotherapy, targeted mutation therapies, radiation, immunotherapy, and on occasion surgery.<sup>7</sup> It is vital that we increase early diagnosis, accurate staging, and referral to the appropriate specialists in lung cancer to ensure that treatment is optimized and more lives are potentially saved.<sup>7</sup>

#### Screening and Diagnosis

Unlike with breast, prostate, and colorectal cancers, systematic screening for lung cancer is not a well-established population-based practice, and its role is not fully grasped by primary caregivers.<sup>15</sup> Risk factors such as history of tobacco use and exposure to second-hand smoke are common knowledge, but other environmental exposures (diesel smoke, pollution,

and other cancer-causing agents) are difficult to quantify.<sup>16,17</sup> Populations with lifestyles with higher exposure to these factors are generally more reticent to intervention and skeptical of the benefits of treatment, while others may be concerned that radiation-based screening techniques contribute to the risk.<sup>15</sup> In addition to patient perceptions that defer intervention, presenting symptoms of cough and dyspnea are frequently confounded with other respiratory conditions, creating a delay in early detection and staging.<sup>9</sup> Even further delays have been seen when patients present with more generalized symptoms like fatigue or bone or joint pain.<sup>9</sup>

Based on the National Lung Screening Trial (NLST),<sup>18</sup> the American College of Chest Physicians (ACCP) has published recommendations that low-dose computerized tomography (LDCT) scans be performed annually on patients meeting the following criteria: (1) 30 pack-year current smoker or former smoker between the ages of 55 and 74 years, (2) former smokers who have quit within the past 15 years, and (3) no comorbidities that potentially preclude curative treatment benefit.<sup>15</sup> The National Comprehensive Cancer Network® (NCCN®) also encourages patients to seek yearly screening if they are 50 years or older, have a 20 or more pack-year smoking history, and have other known risk factors besides second-hand smoke exposure, such as radon exposure.<sup>19</sup> Screening with LDCT, in select patients at high risk for lung cancer, decreased the relative risk of death from lung cancer by 20% when compared with chest radiography.<sup>18</sup> As such, efforts are being made to educate general practitioners and the public about this tremendous benefit.<sup>15,19,20</sup>

The goal of screening is to identify a lung cancer in the earliest possible stage, which, as **Table 1** demonstrates, directly improves survivability.<sup>19</sup> However, imaging alone does not provide accurate staging, and once lung cancer is suspected, time is of the essence in ensuring no further progression. Various target time recommendations have been published advocating for improved wait times across the care spectrum, ranging from 30 to 52 days of median wait time from diagnosis to first treatment.<sup>23,24</sup> Yet one Canadian study showed that despite the recommended time of 2 weeks between symptom onset and diagnosis, the actual median time to diagnosis was 4.5 months.<sup>9</sup> It has been estimated that every 4 weeks between scans represents the potential for a 13% progression.<sup>25</sup> Kasymjanova et al describe 2 studies

and a meta-analysis demonstrating that increased wait times impart a negative effect on recurrence and survival.<sup>23</sup> In their own study, it was noted that reduced wait times particularly benefited Stage III NSCLC survival.<sup>23</sup>

Because pulmonologists may be the first specialist a patient sees, they are relied upon to diagnose, stage, and coordinate care for many patients with lung cancer.<sup>26</sup> Because Stage III NSCLC is a curative intent setting,<sup>13,27</sup> it is of particular importance to coordinate more complicated surgical, radiation, and chemotherapy care for these patients as soon as the diagnosis and stage have been ascertained.<sup>7</sup> While initial chest computed tomography or positron emission tomography (PET) scans often determine tumor size(s) and location(s), and presence of hilar or mediastinal nodes and extrathoracic lesions (excluding the brain), these studies cannot be the sole factors used in staging, and they falsely overstage 19% of the time and understage 13% of the time.<sup>28</sup> The ACCP guidelines recommend magnetic resonance imaging (MRI) of the brain for patients with clinical Stage III or IV disease with or without symptoms of intracranial disease,<sup>29</sup> whereas NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) recommend staging brain MRI in patients with clinical Stage IB (optional), IIA/B, IIIA/B/C and IV.<sup>30</sup>

Diagnostic procedures to obtain accurate histological diagnosis and staging and adequate tissue samples for molecular testing must be considered, ideally with input from a multidisciplinary team (MDT) composed of pulmonologists, thoracic surgeons, and radiology specialists who are board certified and have expertise in thoracic oncology whenever any stage of NSCLC is suspected.<sup>30</sup> PET imaging can be used to identify the optimal biopsy site that produces the highest yield, is minimally invasive, and is most likely to confer the highest staging.<sup>30</sup> Whenever possible, procedures should be combined (bronchoscopy and endobronchial ultrasound with needle aspiration of lymph nodes) to improve time to diagnosis and clinical staging.<sup>30</sup> Invasive mediastinal staging is recommended before surgical resection.<sup>30</sup> The organization of lung cancer care requires development of a multidisciplinary program committed but not limited to the expeditious coordination of the patient's care among various disciplines to avoid unnecessary tests and procedures, delay in care, costly care, and patient frustration and anxiety.<sup>31</sup> Multidisciplinary care has been shown to decrease time to diagnosis and improve referral for appropriate treatment.<sup>32</sup> In particular, patients with Stage III NSCLC are more



#### This article is sponsored by AstraZeneca.

Copyright © 2019 Frontline Medical Communications Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Frontline Medical Communications Inc. and the American College of Chest Physicians will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein. The opinions expressed in this sponsored article do not necessarily reflect the views of the Publisher or the College. All other trademarks are property of their respective owners.

Faculty Disclosure: Dr. Rivera has no financial disclosures to report.

This content was prepared by the specialized content division of Frontline Medical Communications, publisher of *CHEST Physician*.

US-31193

**TABLE 1. Summary of NSCLC Staging & Prognosis<sup>3,21,22</sup>**

Stage	TNM Classification <sup>21</sup> (Tumor, Node, Metastases)	Nodal Zones & Stations <sup>3,22</sup>	Treatment/Goal <sup>22</sup>	5-Year Survival <sup>21</sup>	
IA <sub>1</sub>	T1a or T1a(mi), N0, M0		Surgery or radiation	92%	
IA <sub>2</sub>	T1b, N0, M0		Surgery ± radiation, OR Radiation	83%	
IA <sub>3</sub>	T1c, N0, M0		77%		
IB	T2a, N0, M0		68%		
IIA	T2b, N0, M0		60%		
IIB	T1a-c, N1, M0 <or> T2a-b, N1, M0 <or> T3, N0, M0	N1 = Hilar Zone if ipsilateral • Station 10 (Hilar nodes) Peripheral Zone if ipsilateral • Station 11 (Interlobar nodes) • Station 12 (Lobar Nodes) • Station 13 (Segmental Nodes) • Station 14 (Subsegmental Nodes)	Surgery ± Chemotherapy± Radiation	53%	
IIIA	T1a-c, N2, M0 <or> T2a-b, N2, M0 <or> T3-4, N1, M0 <or> T4, N1, M0	N2 = Lower Zone if ipsilateral • Station 8 (Paraesophageal nodes) • Station 9 (Pulmonary ligament nodes) Subcarinal Zone if ipsilateral • Station 7 (Subcarinal nodes) Aortopulmonary Zone • Station 5 (subaortic & aortopulmonary nodes) • Station 6 (para-aortic nodes) Superior Mediastinal Zone • Station 2 (Upper paratracheal nodes) • Station 3 (Prevascular & retrotracheal nodes) • Station 4 (Lower paratracheal nodes)	Surgery ± Chemotherapy ± Radiation	36%	
IIIB	T3, N2, M0 <or> T4, N2, M0		26%		
IIIA	T1a-c, N2, M0 <or> T2a-b, N2, M0 <or>	N2 = Heterogenous resectability N3 generally non-resectable	Radiation ± Chemotherapy ± Immunotherapy	36-41% <sup>†</sup>	
IIIB	T1a-c, N3, M0 <or> T2a-b, N3, M0 <or> T3, N2, M0 <or> T4, N2, M0		N3 = Supraclavicular Zone • Station 1 (Low cervical, supraclavicular, sternal notch nodes) • contralateral mediastinal, contralateral hilar, ipsilateral/contralateral scalene, superclavicular nodes	Radiation ± Chemotherapy ± Immunotherapy	24-26% <sup>†</sup>
IIIC	T3-4, N3, M0		12-13% <sup>†</sup>		
IVA	Any T, Any N, M1a-b		Palliative Care with Systemic Therapy	0%	
IVB	Any T, Any N, M1c			0%	

Abbreviations: M1a, separate tumor contralateral lobe or primary tumor with pleural/pericardial nodules or malignant effusions; M1b, single extrathoracic mass; M1c, multiple extrathoracic masses; mi, minimally invasive adenocarcinoma.

T1a ≤ 1cm; T1b >1cm, ≤ 2cm; T1c >2cm, ≤ 3cm; T2a >3cm, ≤ 5cm; T2b >4cm, ≤ 5cm; T3 >5cm, ≤ 7cm; T4 >7cm.

<sup>†</sup>Reflects changes in 5-year survival of all stage III NSCLC when staging included pathology information.

likely to receive appropriate treatment when referred to oncology specialists.<sup>7</sup> Still, data suggest that up to 20% of patients diagnosed with Stage III NSCLC are never evaluated by an oncologist.<sup>33</sup>

The tumor, node, metastasis (TNM) system for staging has been used since 1944.<sup>8</sup> Now governed by the International Association for the Study of Lung Cancer (IASLC), the eighth edition took effect in 2017.<sup>21</sup> Several changes from the seventh edition, including new TNM definitions and addition of categories, have caused shifts in staging, with a greater emphasis on tumor size and invasion of surrounding tissues.<sup>3</sup> As a result, Stage III now includes subtype C (T3-T4, N3, M0), which is still treated in a curative intent setting.<sup>21</sup> Additionally, nodal zones were further broken down into more specific stations that clearly define anatomic landmarks within each zone, as this too proved to be associated with prognosis.<sup>3</sup> Differentiating Stage IIIC from Stage IVA has provided more patients the opportunity to be treated in a curative intent setting, as further data collection and new research are expanding within each subtype and allowing for individualized treatment approaches.<sup>3,21</sup>

Clinically, the distinction between resectable and unresectable Stage III

disease is of significance because unresectable Stage III does not afford a treatment path as well-established as resectable disease (surgery).<sup>34</sup> Unresectable generally includes Stage IIIA tumors (T1-T2 tumors with multiple positive ipsilateral mediastinal nodes), often described as bulky or extensive; Stage IIIB (T1-T2 tumors with positive contralateral mediastinal or supraclavicular nodes or T3-T4 tumors with positive ipsilateral mediastinal nodes); and Stage IIIC (T3-T4 tumors with positive contralateral mediastinal or supraclavicular nodes).<sup>11</sup>

### Treatment of Stage III NSCLC

Patients clinically determined to have resectable Stage III NSCLC are candidates for a variety of treatment options, none of which have proven to be superior.<sup>11</sup> The 2019 NCCN Guidelines<sup>®</sup> suggest the following course for resectable Stage III NSCLC: (1) Preoperative chemotherapy (CT) and radiation (CTR), or preoperative CT followed by post-operative RT (split-panel decision); and (2) surgery, using minimally invasive techniques where possible.<sup>30</sup> The panel acknowledges that controversy remains regarding the sequencing of surgery, chemotherapy, and radiation techniques.

The majority of patients with Stage III NSCLC have unresectable disease.<sup>35</sup> Platinum-based CT has been preferred over other chemotherapeutic modalities for over 3 decades.<sup>36</sup> Evidence supports its use as part of definitive CRT along with a minimum of 60 Gy in escalated doses; concurrent treatment is currently preferred over sequential in all histological findings.<sup>30</sup> Accelerated RT alone imparts some benefit to those who refuse CT.<sup>11</sup>

Severe immune-mediated adverse reactions are associated with all immune checkpoint inhibitors, including pneumonitis, causing discontinuation.<sup>37</sup> A recent retrospective single-center study suggests that patients who are on corticosteroids for cancer-unrelated indications have similar outcomes on immunotherapy as patients who are receiving 0 to < 10 mg of prednisone.<sup>37</sup> However, additional mechanistic studies as well as prospective clinical trials are needed to identify whether the use of corticosteroids affects specific aspects of the immune system necessary for immunotherapy activity. Optimal treatment duration for immune checkpoint inhibitors requires further study, and their use in patients with autoimmune disorders and a past organ transplantation should be avoided.<sup>38</sup>

## Conclusion

Locally advanced and metastatic NSCLC patients have benefitted from intensive research into immunologic approaches to treatment. Accurate diagnosis and staging are critical, particularly in the differentiation between Stage III, which is treated with curative intent, and Stage IV, which is metastatic. CRT is the current standard of care for unresectable Stage III disease and has shown improvement in overall survival, while the introduction of immunotherapy following CRT treatment can be discussed as a treatment option. To reap the benefits of these advances in treatment, patients with suspected or confirmed lung cancer should be managed by an MDT that includes a pulmonologist, thoracic surgeon, and medical and radiation oncologists, and referral for appropriate treatment of Stage III and IV NSCLC is crucial to improving patient outcomes.

## References

- National Cancer Institute. <https://seer.cancer.gov/statfacts/html/all.html>. Updated April 15, 2019. Accessed June 14, 2019.
- Molina JR, et al. *Mayo Clin Proc*. 2008;83(5):584-594.
- Rami-Porta R, et al. *CA Cancer J Clin*. 2017;67(2):138-155.
- Detterbeck FC, et al. *CHEST*. 2017;151(1):193-203.
- Nadal E, et al. *Cancer Immunol Immunother*. 2019;68(3):341-352.
- Herzberg B, et al. *Oncologist*. 2017;22(1):81-88.
- Goulart BH, et al. *J Onc Pract*. 2012;9(1):42-50.
- Detterbeck FC, et al. *CHEST*. 2013;143(5 suppl):e191S-e210S.
- Ellis PM, et al. *J Thorac Dis*. 2011;3(3):183-188.
- Agustoni F, et al. *Cancer Treat Rev*. 2019;72:15-27.
- Jones CM, et al. *Curr Surg Rep*. 2018;6(5):2-11.
- Howlader N, et al (eds). National Cancer Institute. [https://seer.cancer.gov/csr/1975\\_2016/](https://seer.cancer.gov/csr/1975_2016/). Published April 2019. Accessed August 19, 2019.
- Socinski MA, et al. *CHEST*. 2013;143(5 suppl):e341S-e368S.
- Zappa C, et al. *Transl Lung Cancer Res*. 2016;5(3):288-300.
- Detterbeck FC, et al. *CHEST*. 2013;143(5 suppl):e78S-e92S.
- Silverman DT, et al. *J Natl Cancer Inst*. 2012;104(11):855-868.
- Eckel SP, et al. *Thorax*. 2016;71(10):891-898.
- Aberle DR, et al. National Lung Screening Trial Research Team. *Radiology*. 2011;258(1):243-253.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Lung Cancer Screening. V.1.2020. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed May 14, 2019. To view the most recent and complete version of the guideline go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding its content, use or application and disclaims any responsibility for its application or use in any way.
- Aberle DR, et al. National Lung Screening Trial Research Team. *N Engl J Med*. 2011;365(5):395-409.
- Goldstraw P, et al. *J Thorac Oncol*. 2016;11(1):39-51.
- Medscape. <https://www.medscape.com/infosites/268834.2/public>. Accessed June 28, 2019.
- Kasymjanova G, et al. *Curr Oncol*. 2017;24(5):302-309.
- Ost DE, et al. *CHEST*. 2013;143(5 suppl):e121S-e141S.
- Mohammed N, et al. *Int J Radiat Oncol Biol Phys*. 2011;79(2):466-472.
- Gaga M, et al. *Am J Respir Crit Care Med*. 2013;188(4):503-507.
- Ramath N, et al. *CHEST*. 2013;143(5 suppl):e314S-e340S.
- Harders SW, et al. *Cancer Imaging*. 2014;14:23.
- Silvestri GA, et al. *CHEST*. 2013;143(5 suppl):e211S-e250S.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Non-Small Cell Lung Cancer. V7.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 30, 2019. To view the most recent and complete version of the guideline go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding its content, use or application and disclaims any responsibility for its application or use in any way.
- Rivera MP. In: Detterbeck FC, et al (eds). *Lung Cancer: A Practical Approach to Evidence-based Clinical Evaluation and Management of Care*. St. Louis, MO: Elsevier; 2018:159-167.
- Freeman RK, et al. *Eur J Cardiothorac Surg*. 2010;38(1):1-5.
- Data on file. US-25141. AstraZeneca Pharmaceuticals LP.
- Patel V, et al. *Oncologist*. 2005;10:335-344.
- Provencio M, et al. *J Thorac Dis*. 2011;3(3):197-204.
- Hellmann MD, et al. *Lancet Oncol*. 2017;18(1):31-41.
- Ricciuti B, et al. *J Clin Oncol*. 2019;37(22):1927-1934.
- Zimmermann S, et al. *Am Soc Clin Oncol Educ Book*. 2018;38:682-695.



# Previously healthy patients hospitalized for sepsis show increased mortality risk

BY MITCHEL L. ZOLER

*MDedge News*

WASHINGTON – Although severe, community-acquired sepsis in previously healthy U.S. adults is relatively uncommon, it occurs often enough to strike about 40,000 people annually, and when previously healthy people are hospitalized for severe sepsis, their rate of in-hospital mortality was double the rate in people with one or more comorbidities who have severe, community-acquired sepsis, based on a review of almost 7 million Americans hospitalized for sepsis.

The findings “underscore the importance of improving public awareness of sepsis and emphasizing early sepsis recognition and treatment in all patients,” including those without comorbidities, Chanu Rhee, MD, said at an annual scientific meeting on infectious diseases. He hypothesized that the increased sepsis mortality among previously healthy patients may have stemmed from factors such as delayed sepsis recognition resulting in hospitalization

at a more advanced stage and less aggressive management.

In addition, “the findings provide context for high-profile reports about sepsis death in previously healthy people,” said Dr. Rhee, an infectious diseases and critical care physician at Brigham and Women’s Hospital in Boston. Dr. Rhee and associates found that, among patients hospitalized with what the researchers defined as “community-acquired” sepsis, 3% were judged previously healthy by having no identified major or minor comorbidity or pregnancy at the time of hospitalization, a percentage that – while small – still translates into roughly 40,000 such cases annually in the United States.

The study used data collected on hospitalized U.S. patients in the Cerner Health Facts, HCA Healthcare, and Institute for Health Metrics and Evaluation databases, which included about 6.7 million people total including 337,983 identified as having community-acquired sepsis, defined as patients who met the



Dr. Chanu Rhee

criteria for adult sepsis advanced by the Centers for Disease Control and Prevention within 2 days of their hospital admission. The researchers looked further into the hospital records of these patients and divided them into patients with one or more major comorbidities (96% of the cohort); patients who were pregnant or had a “minor” comorbidity such as a lipid disorder, benign neoplasm, or obesity (1% of the study group); or those with no chronic comorbidity (3%; the subgroup the researchers deemed previously healthy).

In a multivariate analysis that adjusted for patients’ age, sex, race, infection site, and illness severity at the time of hospital admission the researchers found that the rate of in-hospital death among the previously healthy patients was exactly twice the rate of those who had at least one major chronic comorbidity, Dr. Rhee reported. Differences in the treatment received by the previously healthy patients or in their medical status compared with patients with a major comorbidity suggested that the previously healthy patients were sicker. They had a higher rate of mechanical ventilation, 30%, compared with about 18% for those with a comorbidity; a higher rate of acute kidney injury, about 43% in those previously healthy and 28% in those with a comorbidity; and a higher percentage had an elevated lactate level, about 41% among the previously healthy patients and about 22% among those with a comorbidity.

mzoler@mdedge.com

**SOURCE:** Alrawashdeh M et al. *Open Forum Infect Dis.* 2019 Oct 23;6. Abstract 891.



Subscribe to the  
CHEST e-Learning Library

**CHEST**

Access all CHEST e-Learning products in a whole new way by subscribing to the CHEST e-Learning Library.

**\$99 members\*/\$199 nonmembers**

A 1-year subscription to the CHEST e-Learning Library will include:

- Access to all available CHEST e-Learning activities
- Current opportunities to earn more than 40 CME credits/MOC points
- The option to customize a learning plan specific to your learning style and needs
- Access to over 30 new e-learning products throughout the year

Subscribe today | [chestnet.org/Education/Library/elearning](http://chestnet.org/Education/Library/elearning)

\*International members will receive access to the e-learning portal with their membership fee.

## Rivaroxaban approved for VTE prevention in acutely ill

BY LUCAS FRANKI

*MDedge News*

The Food and Drug Administration has approved rivaroxaban (Xarelto) for the prevention of venous thromboembolism (VTE) in hospitalized, acutely ill patients at risk for thromboembolic complications who do not have a high bleeding risk, according to a release from Janssen.

FDA approval for the new indication is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 hospitalized, acutely ill patients. In MAGELLAN, rivaroxaban demonstrated noninferiority to enoxaparin, a low-molecular-weight heparin, in short-term usage, and it was superior over the long term, compared with short-term enoxaparin followed by placebo.

While VTE and VTE-related deaths were not reduced in MARINER,

compared with placebo, patients who received rivaroxaban did see a significantly reduction in symptomatic VTE with a favorable safety profile.

According to the indication, rivaroxaban can be administered to patients during hospitalization and can be continued after discharge for 31-39 days. The safety profile in MAGELLAN and MARINER was consistent with that already seen, with the most common adverse event being bleeding.

“With this new approval, Xarelto as an oral-only option now has the potential to change how acutely ill medical patients are managed for the prevention of blood clots, both in the hospital and for an extended period after discharge,” said Alex C. Spyropoulos, MD, of Northwell Health at Lenox Hill Hospital, New York, and a member of the steering committee of the MAGELLAN trial.

lfranki@mdedge.com



This advertisement is  
not available for the digital edition.



# Starting PCSK9 in acute-phase ACS under study

BY BRUCE JANCIN

*MDedge News*

PARIS – The first-ever randomized trial of in-hospital initiation of a PCSK9 inhibitor on top of guideline-recommended high-intensity statin therapy in the very-high-risk acute phase of an acute coronary syndrome (ACS) safely resulted in dramatically lower LDL cholesterol levels than with early prescribing of a high-intensity statin alone, Konstantinos C. Koskinas, MD, reported at the annual congress of the European Society of Cardiology.

At 8 weeks of follow-up, 90% of the dual-therapy group had achieved the new ESC guideline-recommended target of an LDL cholesterol less than 55 mg/dL, compared with 11% of patients randomized to high-intensity atorvastatin at 40 mg/day plus placebo injections. Moreover, 96% of patients on atorvastatin 40 mg/day plus evolocumab at 420 mg per subcutaneous injection were below the former target of an LDL cholesterol less than 70 mg/dL, as were 38% of those on the high-intensity statin alone, according to Dr. Koskinas, a cardiologist at the University of Bern (Switzerland).

The seven-center Swiss EVOPACS trial, featuring 308 ACS patients, could be considered a proof-of-concept study, as it lacked the size and duration to be powered to assess clinical outcomes.

“The clinical impact of very early LDL lowering with evolocumab initiated in the acute setting of ACS warrants further investigation in a dedicated cardiovascular outcomes trial,” Dr. Koskinas asserted. “We see this as the natural next step. Discussions are underway about a long-term trial with clinical

endpoints, but no decisions have been made.”

The rationale for the EVOPACS trial is based upon current standard practice in ACS management, which includes initiation of a high-intensity statin during the acute phase of ACS, a particularly high-risk period for recurrent events. This practice has a Class IA recommendation in the guidelines based on published evidence that it results in a significantly reduced rate of the composite of death, MI, or rehospitalization for ACS within 30 days, compared with a less aggressive approach to LDL cholesterol lowering.

Yet even though the PCSK9 inhibitors are the 800-lb gorillas of LDL cholesterol lowering, they’ve never been tested in the setting of acute-phase ACS. For example, in the landmark ODYSSEY OUTCOMES trial, alirocumab was initiated on average 2.6 months after ACS, while in FOURIER the lag time between ACS and the start of evolocumab was 3.4 years, the cardiologist noted.

In contrast, all of the 37% of EVOPACS participants with an ST-segment elevation MI were enrolled in the study and on treatment within 24 hours after symptom onset. So were more than one-third of those with non-ST-elevation ACS, with the remainder getting onboard 24-72 hours after symptom onset.

The safety and tolerability of dual LDL cholesterol-lowering therapy were excellent in the brief EVOPACS study. There were no significant between-group differences in adverse events or serious adverse events, nor in prespecified events of special interest, including muscle pain, neurocognitive changes, or elevated liver enzyme levels.

The LDL cholesterol lowering achieved with

## VIEW ON THE NEWS

**G. Hossein Almassi, MD, FCCP, comments:**

PCSK9 inhibitors are monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin 9 in the liver leading to a profound lowering of the LDL cholesterol in the blood. But unlike statins, these drugs are used by injection. By targeting the patients with ACS and starting the drug early after the event, this trial showed dramatic lowering of the LDL cholesterol. Whether the clinical outcomes will follow the lower LDL level was not addressed by this trial and we will have to wait the results of larger trials focused on patients’ clinical outcomes.



dual therapy in EVOPACS was jaw dropping: Over the course of 8 weeks, the mean LDL cholesterol went from 132 to 31 mg/dL. In patients on early high-intensity atorvastatin alone, LDL cholesterol went from 139 to 80 mg/dL.

The full details of the EVOPACS trial have been published (*J Am Coll Cardiol.* 2019 Aug 16. doi: 10.1016/j.jacc.2019.08.010).

The trial was funded by Amgen. Dr. Koskinas reported receiving honoraria from Amgen and Sanofi.

[bjancin@mdedge.com](mailto:bjancin@mdedge.com)

# Insomnia symptoms increase likelihood of stroke

BY JAKE REMALY

*MDedge News*

The presence of insomnia symptoms increases the likelihood of cardiovascular or cerebrovascular disease during approximately 10 years of follow-up, according to a large cohort study of adults in China. A greater number of insomnia symptoms is associated with increased risk, and this relationship is more evident in younger adults and in adults without hypertension at baseline, researchers reported Nov. 6 in *Neurology*.

“These results suggest that, if we can target people who are having trouble sleeping with behavioral therapies, it’s possible that we could reduce the number of cases of stroke, heart attack, and other diseases later down the line,” study author Liming Li, MD, professor of epidemiology at Peking University, Beijing, said in a news release.

To clarify the relationships between individual insomnia symp-

toms, cardiocerebral vascular diseases, and potential effect modifiers, Dr. Li and colleagues analyzed data from the China Kadoorie Biobank Study. For this study, more than 500,000 adults in China aged 30-79 years completed a baseline survey during 2004-2008. The present analysis included data from 487,200 participants who did not have a history of stroke, coronary heart disease, or cancer at baseline.

For the baseline survey, participants answered questions about whether specific insomnia symptoms occurred at least 3 days per week during the past month. The symptoms included difficulty initiating or maintaining sleep (that is, sleep-onset latency of 30 minutes or more after going to bed or waking up in the middle of the night); waking too early and being unable to fall back asleep; and trouble functioning during the day because of bad sleep.

The researchers assessed the incidence of cardiocerebral vascular

## VIEW ON THE NEWS

**G. Hossein Almassi, MD, FCCP, comments:** The results of this large observational study are interesting, especially for those of us treating patients with sleep disorders. Patients baseline characteristics such as older age, female gender, and low socioeconomic and education profile are known risk factors for higher cardiovascular events. The study, however, did not look at the impact of these patients’ baseline profiles on the higher incidence of cardiocerebral vascular events.

diseases through 2016 by examining disease registries, national health insurance claims databases, and local records. Investigators identified participants with any cardiocerebral vascular disease and assessed the incidence of ischemic heart disease, acute myocardial infarction, hemorrhagic stroke, and ischemic stroke. The researchers followed each participant until the diagnosis of a cardiocerebral vascular disease outcome, death from any cause, loss to follow-up, or Dec. 31, 2016. The researchers used Cox proportional hazard models

to estimate hazard ratios for the association between each insomnia symptom and cardiocerebral vascular disease outcomes. They adjusted the models for established and potential confounding factors, including age, income, smoking status, diet, and physical activity.

## More than 16% had any insomnia symptom

Of the 487,200 participants, 11.3% had difficulty initiating or maintaining sleep, 10.4% had early-morning awakening, and 2.2% had

*Continued on following page*



Continued from previous page

daytime dysfunction attributed to poor sleep. Compared with participants without insomnia symptoms, participants with insomnia symptoms tended to be older and were more likely to be female, not married, and from a rural area. In addition, those with insomnia symptoms were more likely to have depression or anxiety symptoms, lower education level, lower household income, and lower body mass index. They also were more likely to have a history of diabetes mellitus. During a median follow-up of 9.6 years, 130,032 cases of cardiocerebral vascular disease occurred, including 40,348 cases of ischemic heart disease and 45,316 cases of stroke.

After adjustment for potential confounders, each insomnia symptom was associated with greater risk of cardiocerebral vascular disease. For difficulty initiating or maintaining sleep, the hazard ratio was 1.09. For early-morning awakening, the HR was 1.07. For daytime dysfunction, the HR was 1.13. Each insomnia symptom was associated with increased risk of ischemic heart disease and ischemic stroke, whereas only difficulty initiating or maintaining sleep was associated with increased risk of acute MI.

In all, 16.4% of participants reported any insomnia symptom; 10% had one symptom, 5.2% had two symptoms, and 1.2% had three symptoms. “Compared with those without any insomnia symptoms, participants with one, two, or three symptoms had a 7%, 10%, or 18% higher risk of total [cardiocerebral vascular disease] incidence, respectively,” the authors wrote. “Our study is the first large-scale cohort study that identified positive dose-response relationships between the number of insomnia symptoms and risks of [cardiocerebral vascular diseases, ischemic heart disease] and stroke incidence.”

#### Opportunity for intervention

Compared with clinical diagnostic criteria for insomnia, “individual insomnia symptoms are better defined and more feasible to assess with questionnaires in large-scale population studies and clinical practice,” Dr. Li and colleagues wrote. “Moreover, it is reasonable that insomnia symptoms are more modifiable and precisely targetable through behavioral therapies before developing into clinically significant insomnia disorder. Therefore, future clinical trials or community-based intervention

studies should be conducted to test whether lifestyle or sleep hygiene interventions for insomnia symptoms can reduce subsequent [cardiocerebral vascular disease] risks.”

The results suggest that efforts aimed at early detection and intervention should include a focus on younger adults and people who do not have

high blood pressure, Dr. Li said.

This study was supported by the National Key Research and Development Program of China, the Chinese Ministry of Science and Technology, and the National Natural Science Foundation of China. The China Kadoorie Biobank surveys were supported by grants

from the Kadoorie Charitable Foundation and the U.K. Wellcome Trust. The authors had no relevant disclosures.

[jremaly@mdedge.com](mailto:jremaly@mdedge.com)

**SOURCE:** Zheng B et al. *Neurology*. 2019 Nov 6. doi: 10.1212/WNL.0000000000008581.

This advertisement is  
not available for the digital edition.

 **CHEST**<sup>™</sup> Physician  
THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

# Dupilumab effective in early- and late-onset asthma

BY JENNIFER SMITH

MDedge News

**FROM CHEST 2019** ■ NEW ORLEANS – A new analysis suggests dupilumab is beneficial for patients with early- or late-onset asthma.

Dupilumab may be more effective in reducing severe asthma exacerbations in patients with late-onset asthma, but the drug's effect on lung function appeared the same regardless of asthma onset. Nicola Hanania, MD, of Baylor College of Medicine in Houston presented these results at the annual meeting of the American College of Chest Physicians.

Dr. Hanania and colleagues conducted a subanalysis of the LIBERTY ASTHMA QUEST study (NCT02414854). Previous data from this study showed that patients with uncontrolled, moderate to severe asthma who received dupilumab had fewer exacerbations and better lung function than did patients who received placebo (N Engl J Med. 2018;378:2486-96).

In their subanalysis, Dr. Hanania and his colleagues evaluated the efficacy of dupilumab, given at 200 mg or 300 mg every 2 weeks, in patients with early-onset asthma (at 40 years of age or younger) and late-onset asthma



Dr. Nicola Hanania

(at 41 years or older). The analysis included 919 patients with early-onset asthma who received dupilumab and 450 early-onset patients who received placebo. There were 345 patients with late-onset asthma who received dupilumab and 188 late-onset patients who received placebo.

## Exacerbations

Dupilumab significantly reduced the adjusted annualized severe exacerbation rates during the 52-week treatment period. Significant reductions occurred in both early- and late-onset patients, though reductions were greater in the late-onset group.

In early-onset patients, dupilumab reduced severe exacerbations by 38% when given at 200 mg and by 37% when given at 300 mg (*P* less than .001 vs. placebo). In late-onset patients, dupilumab reduced exacerbations by 64% and 69%, respectively (*P* less than .001 vs. placebo).

Dr. Hanania went on to note that reductions in exacerbation rates were greatest in patients with elevated blood eosinophils (150 cells/mcL or greater) or fractional exhaled nitric oxide (FeNO; 25 ppb or greater).

In patients with early-onset asthma and elevated eosinophils, dupilumab reduced severe exacerbations by 50% when given at 200 mg and by 55% when given at 300 mg (*P* less than .001 vs. placebo). In late-onset patients with elevated eosinophils, dupilumab reduced exacerbations by 65% and 73%, respectively (*P* less than .001 vs. placebo).

In patients with early-onset asthma and elevated FeNO, dupilumab reduced severe exacerbations by 56% when given at 200 mg and by 52% when given at 300 mg (*P* less than .001 vs. placebo). In late-onset patients with elevated FeNO, dupilumab reduced exacerbations by 79% and 71%, respectively (*P* less than .001 vs. placebo).

## Lung function

Dupilumab also improved pre-bronchodilator forced expiratory volume in 1 second (pre-BD FEV<sub>1</sub>), compared with placebo, with similar results in early- and late-onset patients.

In early-onset patients, the *P* values were less than .001 for both doses of dupilumab at weeks 12 and 52. In late-onset patients, the *P* values were less than .001 for the 300-mg dose at week 12 and the 200-mg dose at week 52, less than .01 for the 200-mg dose at week 12, and less than .05 for the 300-mg dose at week 52.

The effects of dupilumab on pre-BD FEV<sub>1</sub> were greatest in patients with elevated eosinophils or FeNO. At week 12, the *P* value was less than .001 for both doses of dupilumab in early-onset patients with elevated eosinophils or FeNO.

This research was sponsored by Sanofi and Regeneron. Dr. Hanania disclosed relationships with Genentech, Novartis, AstraZeneca, Boehringer Ingelheim, GSK, Regeneron, and Sanofi.

jensmith@mdedge.com

**SOURCE:** Hanania N et al. CHEST 2019; Abstract. doi: 10.1016/j.chest.2019.08.870.

# Omalizumab results for asthma varied with fixed airflow obstruction, reversibility

BY JENNIFER SMITH

MDedge News

**FROM CHEST 2019** ■ NEW ORLEANS – A new analysis suggests omalizumab reduces exacerbations in patients with severe, uncontrolled asthma, regardless of fixed airflow obstruction (FAO). However, exacerbation reductions were greatest in patients with high reversibility, and omalizumab only improved lung function significantly in FAO-negative patients with high reversibility.

Nicola Hanania, MD, of Baylor College of Medicine, Houston, presented these findings at the annual meeting of the American College of Chest Physicians.

The findings are from a post hoc analysis of the phase 3 EXTRA study (NCT00314574). This 48-week study enrolled patients who had inadequately controlled, severe asthma despite receiving high-dose inhaled corticosteroids and long-acting beta-agonists.

The patients were randomized to receive omalizumab (n = 427) or placebo (n = 421). Baseline characteristics were similar between the treatment arms.

FAO presence was defined as a postbronchodilator FEV<sub>1</sub>/FVC (forced expiratory volume in 1

second/forced vital capacity) ratio less than 70%. High reversibility was defined as an increase in FEV<sub>1</sub> of 12% or greater after albuterol administration.

Omalizumab reduced exacerbations regardless of FAO, but the exacerbation relative rate reductions were greatest in FAO-positive and -negative subgroups with high reversibility.

The exacerbation relative rate reductions with omalizumab versus placebo were as follows:

- 24.8% in the overall population.
- 6.0% in FAO-positive patients with low reversibility.
- 59.8% in FAO-positive patients with high reversibility.
- 17.4% in FAO-negative patients with low reversibility.
- 44.3% in FAO-negative patients with high reversibility.

“So bronchodilator reversibility at baseline was ... a correlate of more significant exacerbation reduction than ... low reversibility,” Dr. Hanania said. “But the fixed airflow obstruction, whether it was present or not, did not really matter.”

As for lung function improvement, omalizumab conferred a marginal benefit for the overall population, but the improvement was “much

more significant” in the FAO-negative patients with high reversibility, according to Dr. Hanania.

At week 48, the least-square mean treatment difference (omalizumab vs. placebo) for absolute FEV<sub>1</sub> change from baseline was:

- 68 mL in the overall population.
- 17 mL in FAO-positive patients with low reversibility.
- 2 mL in FAO-positive patients with high reversibility.
- 34 mL in FAO-negative patients with low reversibility.
- 104 mL in FAO-negative patients with high reversibility.

“As lung function improvement by omalizumab appeared to be driven by reversibility, asthma with lower reversibility and fixed airflow obstruction may represent a different phenotype,” Dr. Hanania said. “I think this needs to be looked at.”

This research was funded by Genentech and Novartis. Dr. Hanania disclosed relationships with Genentech, Novartis, AstraZeneca, Boehringer Ingelheim, GSK, Regeneron, and Sanofi.

jensmith@mdedge.com

**SOURCE:** Hanania N et al. CHEST 2019; Abstract. doi: 10.1016/j.chest.2019.08.869.



# Physicians, patients may overestimate asthma control

BY JENNIFER SMITH

*MDedge News*

**FROM CHEST 2019** ■ NEW ORLEANS – Physicians and patients both overestimate control of severe asthma, according to an observational study.

More than half (53%) of cases physicians rated as controlled were actually uncontrolled according to the Asthma Control Test (ACT), and 30% of patients who considered their asthma controlled actually had uncontrolled asthma according to the ACT.

Reynold A. Panettieri Jr., MD, of Rutgers University in New Brunswick, N.J., presented these findings at the annual meeting of the American College of Chest Physicians.

The findings are from CHRONICLE study, an ongoing observational study of adults with severe asthma who are being treated by U.S. allergists or pulmonologists. The study enrolled 796 patients during Feb. 2018–Feb. 2019, and 482 of them were evaluable because they completed the necessary surveys.

Patients received care from an allergist (49%), a pulmonologist (38%), or both (13%). Patients were treated with biologics (n = 370), maintenance systemic corticosteroids (n = 64), or high-dosage inhaled corticosteroids with additional controllers (n = 90).

At patient enrollment, physicians reported their assessment of patients' asthma control and completed the 5-point Global Evaluation of Treatment Effectiveness (GETE). The physicians' assessments of patients were informed by the patients' verbal reports (50%), lung function testing (44%), in-office ACT (41%), and recent exacerbations (39%).

Patients also completed the ACT and GETE online at the time of enrollment. Neither patients nor physicians were privy to the other group's responses.

Overall, physicians said 279 patients had controlled asthma. However, according to the ACT, 27% of these cases were very poorly controlled, 26% were not well controlled, and 47% were well controlled.

“So [when] we as a provider say the patient's controlled, we're wrong half the time,” Dr. Panettieri said.

However, physicians were more accurate when deeming patients' asthma uncontrolled. Physicians said 201 cases of asthma were uncontrolled, and the ACT said 64% of these cases were very poorly controlled, 22% were not well controlled, and 13%

were well controlled.

Compared with the physicians' results, the patients' reports were more in line with ACT results. However, the patients still overestimated control.

“About 99% of the time, when

a patient tells you they're uncontrolled, they're uncontrolled by the ACT,” Dr. Panettieri said.

This study is supported by AstraZeneca. Dr. Panettieri disclosed relationships with AstraZeneca, Sanofi,

Regeneron, Genentech, and Novartis.  
jensmith@mdedge.com

**SOURCE:** Panettieri RA et al. CHEST 2019; Abstract. doi. 10.1016/j.chest.2019.08.272.

This advertisement is  
not available for the digital edition.

 **CHEST**<sup>™</sup> Physician  
THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

# Digital inhaler reveals uncontrolled asthma

BY JENNIFER SMITH

*MDedge News*

**FROM CHEST 2019** ■ NEW ORLEANS – Data collected by the ProAir Digihaler suggest patients with pre-

vious, but not current, severe clinical asthma exacerbations may still use their rescue inhalers daily and therefore require additional therapy.

Researchers studied asthma patients who had experienced

exacerbations in the previous year. Patients who also had exacerbations while on study used the ProAir Digihaler about twice a day, on average. Patients without on-study exacerbations used the

ProAir Digihaler an average of 1.14 times per day.

The daily use among patients without exacerbations suggests their asthma is “still quite uncontrolled,” and, according to guidelines, they may

This advertisement is  
not available for the digital edition.

 **CHEST**<sup>™</sup> Physician  
THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS



require additional therapy, said Roy Pleasants, PharmD, of the University of North Carolina at Chapel Hill.

Dr. Pleasants presented these findings at the annual meeting of the American College of Chest Physicians.

He and his colleagues conducted a phase 3 study (NCT02969408) of

ProAir Digihaler use in adults who had at least one severe clinical asthma exacerbation in the previous 12 months. They had an Asthma Control Questionnaire score of 1.5 or greater, were on moderate-dose inhaled corticosteroids (with or without a long-acting beta-agonist), and had stable asthma controller dosing

for at least 3 months.

For this study, the ProAir Digihaler replaced patients' other rescue medications. The ProAir Digihaler is a digital inhaler that delivers 90 mcg of albuterol per dose, detects the date and time a dose was prepared, and records the inhalation profile. Over a 12-week

period, the ProAir Digihaler recorded each use, which was defined as consecutive inhalations within 60 seconds.

Of the 381 patients enrolled in the study, 360 (94.5%) made at least one valid inhalation. The mean age of these patients was 50 years, and 80.6% were female. Of the 360 patients, 64 experienced 78 exacerbations while on study.

Most episodes of inhaler use consisted of a single inhalation (58.9%), although 35.8% consisted of two inhalations, 3.5% consisted of three

This advertisement is  
not available for the digital edition.

 **CHEST**™ Physician  
THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS



Dr. Roy Pleasants

inhalations, and 1.8% consisted of four or more inhalations.

The mean peak inspiratory flow was 73.18 L/min (standard deviation [SD], 20.33) in patients without exacerbations. Among patients with exacerbations, the mean peak inspiratory flow was 71.36 (SD, 23.80) during exacerbation and 74.71 L/min (SD, 22.46) outside the exacerbation window, which was 14 days before and after the exacerbation peak.

The mean inhalation volume was 1.45 L (SD, 0.75) among patients without exacerbations, 1.44 L (SD, 0.66) outside the exacerbation window, and 1.44 L (SD, 0.76) during exacerbation. The mean inhalation duration was 1.62 sec (SD, 0.88), 1.59 sec (SD, 0.77), and 1.61 sec (SD, 0.82), respectively.

“If you look at the inhalation volume in the 64 patients who exacerbated, it really didn’t change during exacerbation,” Dr. Pleasants noted. “Essentially, you can say the same thing about inhalation duration.”

This study was sponsored by Teva, makers of the ProAir Digihaler. Dr. Pleasants disclosed relationships with Teva, Grifols, Sunovion, and Boehringer Ingelheim.

[jensmith@mdedge.com](mailto:jensmith@mdedge.com)

**SOURCE:** Pleasants R et al. CHEST 2019; Abstract. doi: 10.1016/j.chest.2019.08.273.

# Tide beginning to turn on vaccine hesitancy

BY DOUG BRUNK

*MDedge News*

NEW ORLEANS – In the opinion of Paul A. Offit, MD, pushback against antivaccination campaigns and advocates is stronger than ever.

The shift began with the measles outbreak in Southern California in late 2014, he said. According to the Centers for Disease Control and Prevention, 125 measles cases with rash that occurred between Dec. 28, 2014, and Feb. 8, 2015, were confirmed in U.S. residents. Of these, 100 were California residents (MMWR. 2015 Feb 20;64[06];153-4).

“This outbreak spread ultimately to 25 states and involved 189 people,” Dr. Offit said at the annual meeting of the American Academy of Pediatrics. “It was in the news almost every day. As a consequence, there were measles outbreaks in New York, New Jersey, Florida, Oregon, and Texas, and Washington, which began to turn the public sentiment against the antivaccine movement.”

Even longstanding skeptics are changing their tune. Dr. Offit, professor of pediatrics in the division of infectious diseases at the Children’s Hospital of Philadelphia, cited a recent study from the Autism Science Foundation which found that 85% of parents of children with autism spectrum disorder don’t believe that vaccines cause the condition. “Although there will be parents who continue to believe that vaccines cause autism, most parents of children with autism don’t believe that,” he said. “Also, it’s a little hard to make your case that vaccines are dangerous and that you shouldn’t get them in the midst of outbreaks.”

Perhaps the greatest pushback against antivaccination efforts has been made in the legal arena. In 2019 alone, legislators in California banned parents from not vaccinating their kids because of personal beliefs, while lawmakers in New York repealed the religious exemption to vaccinate, those in Maine repealed the religious and philosophical exemption, those in New Jersey required detailed written explanation for religious exemption, and those in Washington State repealed the

philosophical exemption for the MMR vaccine.

Pushback also is apparent on various social media platforms. For example, Dr. Offit said, Pinterest restricts vaccine search results to curb the spread of misinformation, YouTube removes ads from antivaccine channels, Amazon Prime



Dr. Paul A. Offit

has pulled antivaccination documentaries from its video service, and Facebook has taken steps to curb misinformation about vaccines. “With outbreaks and with children suffering, the media and public sentiment has largely turned against those who are vehemently against vaccines,” he said. “I’m talking about an angry, politically connected, lawyer-backed group of people who are conspiracy theorists, [those] who no matter what you say, they’re going to believe there’s a conspiracy theory to hurt their children and not believe you. When that group becomes big enough and you start to see outbreaks like we’ve seen, then it becomes an issue. That’s where it comes down to legislation. Is it your inalienable right as a U.S. citizen to allow your child to catch and transmit a potentially fatal infection? That’s what we’re struggling with now.”

When meeting with parents who are skeptical about vaccines or refuse their children to have

them, Dr. Offit advises clinicians to “go down swinging” in favor of vaccination. He shared how his wife, Bonnie, a pediatrician who practices in suburban Philadelphia, counsels parents who raise such concerns. “The way she handled it initially was to do the best she could to eventually get people vaccinated,” he said. “She was successful about one-quarter of the time. Then she drew a line. She started saying to parents, ‘Look; don’t put me in a position where you are asking me to practice substandard care. I can’t send them out of this room knowing that there’s more measles out there, knowing that there’s mumps out there, knowing that there’s whooping cough out there, knowing that there’s pneumococcus and varicella out there. If this child leaves this office and is hurt by any of those viruses or bacteria and I knew I could have done something to prevent it, I couldn’t live with myself. If you’re going to let this child out without being vaccinated I can’t see you anymore because I’m responsible for the health of this child.’ With that [approach], she has been far more successful. Because at some level, if you continue to see that patient, you’re tacitly agreeing that it’s okay to [not vaccinate].”

In 2000, Dr. Offit and colleagues created the Vaccine Education Center at Children’s Hospital of Philadelphia, which provides complete, up-to-date, and reliable information about vaccines to parents and clinicians. It summarizes the purpose of each vaccine, and the relative risks and benefits in easy-to-read language. The CDC also maintains updated information about vaccines and immunizations on its web site. For his part, Dr. Offit tells parents that passing on an opportunity to vaccinate their child is not a risk-free choice. “If you choose not to get a vaccine you probably will get away with it, but you might not,” he said. “You are playing a game of Russian roulette. It may not be five empty chambers and one bullet, but maybe it’s 100,000 empty chambers and one bullet. There’s a bullet there.”

Dr. Offit reported having no relevant financial disclosures.

dbrunk@mdedge.com

## Repeat pneumococcal disease may signal immunodeficiency

BY BIANCA NOGRADY

*MDedge News*

Recurrent invasive pneumococcal disease in children could be a signal of underlying primary immunodeficiency, according to a study published in *JAMA Pediatrics*.

Coen Butters, BMed, DCH, of the Royal Children’s Hospital, Melbourne, wrote that, even with optimal vaccine coverage, there are still children with increased susceptibility to invasive pneumococcal disease (IPD), and this could be a potential marker of primary immunodeficiency.

They conducted a systematic review of 17 studies of 6,002 children to ex-

amine the evidence on the incidence of primary immunodeficiency in children who presented with IPD but without any other risk factors or predisposing conditions. Overall, the frequency of primary immunodeficiency in children presenting with IPD who did not have any other predisposing condition was 1%-26%.

One study of 162 children with IPD, which had an overall frequency of primary immunodeficiency of 10%, found that children older than 2 years were significantly more likely to have primary immunodeficiency than those aged under 2 (26% vs. 3%).

Primary antibody deficiency was the most commonly diagnosed im-

munodeficiency in these children with IPD, accounting for 71% of cases. These deficiencies presented as hypogammaglobulinemia, specific pneumococcal antibody deficiency, X-linked agammaglobulinemia, and IgG2 deficiency.

The review also included four studies that looked at the frequency of mannose-binding lectin deficiency in 1,493 children with primary IPD. Two of these studies reported a prevalence of mannose-binding lectin deficiency ranging from 31% in children aged younger than 2 years to 41% in children younger than 1 year.

Five studies looked at the rate of primary immunodeficiency in chil-

dren presenting with recurrent IPD. In addition to other predisposing conditions such as sickle cell disease, cancer, and anatomical breach in the blood-brain barrier, the three studies that screened for primary immunodeficiency found rates ranging from 10% to 67%. The most common conditions were complement deficiency, pneumococcal antibody deficiency, and a single case of TLR-signaling defect.

The authors declared no conflicts.

chestphysiciannews@chestnet.org

**SOURCES:** Butters C et al. *JAMA Pediatrics*. 2019 Sep 30. doi: 10.1001/jama-pediatrics.2019.3203.

**This advertisement is  
not available for the digital edition.**





# Environmental scan: Drivers of philanthropy

BY THERESE BORDEN

MDedge News

Philanthropy is a driving force supporting and promoting pioneering research and programs in many fields of medicine. Charitable giving, foundation support, and grants touch the lives of millions of patients and also have an impact across all fields of medical practice. Four factors stand out as most likely to have a significant influence on philanthropy decisions in the coming years. These include advancements in technology, ability

**CHEST**  
**INSPIRATION:**

Pacing the Future

to make an impact, accountability, and the recent tax reform laws. Donors want more information and more options for giving. They want to know how their dollars are being used and the impact of their donation. Individuals donate to causes and organizations that are important to them and reflect their values. In addition, what motivates Baby Boomers and Gen Xers to give frequently differs from what factors into the giving decisions of Millennials.



Dr. Addrizzo-Harris

In 2019, Charity Navigator reported total giving to charitable organizations was \$427.1 billion, 0.7% measured in current dollars over the revised total of \$424.74 billion contributed in 2017.<sup>1</sup>

Doreen Addrizzo-Harris, MD, FCCP, Professor of Medicine, NYU School of Medicine, and Past President of CHEST Foundation, has observed these trends in philanthropy first hand. “Overall total giving has decreased by 1.7%. However, giving to foundations has increased by 7.3% during the same time period. The CHEST Foundation wants to take advantage of this change. People, particularly Millennials, want to feel more connected with the organizations that they give to. They want to know where their donations are going, and they want to have more of a personal connection with the organization or foundation.”

## Impact investing, transparency, and trust

As donors become more focused on results, organizations will need to demonstrate their ability to achieve short-term goals that bring them closer to accomplishing their mission and vision. This sentiment may be strongest among Millennials. Nonprofit organizations should expect an increased level of due diligence and a higher level of personal involvement by donors.<sup>2</sup>

## Health care–related issues

Two of the top three issues identified by donors as a challenge to be addressed are related to health care, according to Fidelity Charitable. Thirty-nine percent identified “developing treatment or cures for a disease” and 33% cited “access to basic health services” as priority issues. A study by Giving

USA estimated that charitable giving to health-care organizations rose a strong 7.3% (5.5% adjusted for inflation) in 2017, but giving that year was fueled by a booming stock market and a favorable tax environment. Charitable donations to hospitals tend to reflect the economic health of the community in which the institution is located. Donations to rural hospitals in depressed communities are likely to be far less than to urban institutions in economically strong areas.<sup>3</sup>

## Tax reform

The Tax Cuts and Jobs Act of 2017 will likely affect donations to charitable organizations in 2019. Specifically, the 2017 Tax Act doubled the standard tax deduction, thereby reducing the number of households having to itemize their deductions and eliminating many tax benefits for charitable donations. Middle-class families are expected to opt for the standard deduction while wealthier taxpayers will likely continue itemizing their deductions. As a result, some predict that donors may switch from giving annually to giving every third year so they can itemize in their giving years to get the deduction.<sup>4</sup>

## Technology and peer-to-peer giving

Technological advances that make researching and giving easier and more convenient are likely to have a significant impact on many charitable organizations in 2019. Online donations are likely to increase as organizations make it simple to donate from mobile devices, social media platforms, and their websites. Although charitable organizations will continue to directly ask individuals for a donation, many are expanding their efforts to include online social campaigns that leverage peer-to-peer giving. Other technological advancements likely to affect donations in the future include the ability for organizations to incorporate contactless payment programs and blockchain technology.<sup>5</sup>

## Generational differences in giving

Although the trends identified above are likely to affect the decision to give in 2019, there are some meaningful differences in how different generations embrace these changes. Technological advances, the rise of alternative forms of giving, and increased opportunities to connect with peers about giving influence Millennials significantly more than Baby Boomers. Millennials are more likely to say that they give to make a meaningful difference while Boomers are likely to say that giving is part of their values. Millennials also are more likely to say their giving is more spontaneous, while Boomers say their giving is more planned. As many as 49% of Millennials cite technological advances influencing their giving, compared with only 23% of Baby Boomers. This trend continues for the rise of alternative forms of giving (32% of Millennials, compared with 14% of Boomers) and increased opportunities to connect with peers about giving (30%, compared with 11%).

Twenty-nine percent of Millennials are very optimistic about philanthropy’s ability to solve the

issues most important to them, compared with only 15% of Baby Boomers. Both generations prioritize challenges related to health, hunger, and the environment.<sup>6</sup>

Today, foundations need to focus on impact, not just education programs or scholarships. New tech-driven trends in giving, such as the emergence of digital peer-to-peer giving and crowdfunding campaigns, make it possible to tap into high-volume, small-amount donations. To recruit new donors, organizations will need to target their messages based on the audience segment.

Dr. Addrizzo-Harris notes that the CHEST Foundation is responding to these trends. “The

Continued on page 27



Continued from page 24

CHEST Foundation is working to become more patient- and community-friendly and to reach out beyond their physician member pool. The Foundation allows patients, their families, and physicians to feel like they are actively involved with programs that include community health projects, patient education material, or fundraising events. Recently, we have changed our giving platform to be more technology-friendly. We also have expanded the ways a potential donor can give by now including text and expanded online giving sites.

She continued, "We are also actively revamping our website to enhance our communication with our physician members, patients, their families, and their communities by making disease-specific sites that help with empowering the patient and the physician to have access to expert care. We have expanded our fundraising events to include patients and their families and interested nonphysician members in the communities. Many of our events focus on families who want to help other patients have better access to care. Events such as the Feldman Family Poker event this past March and the upcoming *Golden Era of EP* event, an evening celebrating Erin Popovich and the launch of the new endowment bearing her name, highlight ways that the CHEST Foundation is working with families to promote disease awareness and help enhance access to care.

Dr. Addrizzo-Harris concluded, "We hope that by more effectively engaging our donors, we will in-

**Note: Background research performed by Avenue M Group.**

*CHEST Inspiration is a collection of programmatic initiatives developed by the American College of Chest Physicians leadership and aimed at stimulating and encouraging innovation within the association. One of the components of CHEST Inspiration is the Environmental Scan, a series of articles focusing on the internal and external environmental factors that bear on success currently and in the future. See "Envisioning the Future: The CHEST Environmental Scan," CHEST Physician, June 2019, p. 44, for an introduction to the series.*

crease total giving as they will feel a personal connection to the CHEST Foundation."

**References**

1. Giving USA 2019: Annual report for philanthropy for 2018. <https://tinyurl.com/y28q8uye>.

2. Fidelity Charitable (2019) Future of philanthropy. <https://tinyurl.com/ussj5v9>

3. Betzebe, Philip (2018) Charitable giving to health giving to health organizations rose 7.3% last year. Health Leaders. July 11. <https://tinyurl.com/tnn5h5g>

4. Martis & Landy/Indiana University Lilly Family School of Philanthropy (2018) The

Philanthropy Outlook 2018 & 2019. <https://tinyurl.com/vpo3toe>

5. M&R Benchmarks 2019. <https://tinyurl.com/y47x2ab7>

6. Nonprofit Source (2019) The ultimate list of charitable giving statistics for 2018. <https://tinyurl.com/saeoyzn>



## The Evolving Role of the Pulmonologist and Primary Care Physician in Patient Identification and Treatment of Non-Small Cell Lung Cancer (NSCLC)

LIVE WEBINAR PROGRAM

**Monday, January 13, 2020**  
**1:00 PM - 2:00 PM ET**

**Join this engaging and interactive webinar presented by a multidisciplinary team.**

**Objectives:**

- Review the epidemiology of NSCLC
- Examine the patient journey for NSCLC from symptoms or screening to diagnosis
- Evaluate treatment advances in locally-advanced NSCLC
- Discuss the appropriate use of targeted therapy and immunotherapy in metastatic NSCLC

**A question-and-answer session with 3 expert presenters to follow the live presentation.**

**Presenters:**



**Tracey Evans, MD**  
Director, Thoracic Oncology Research  
Co-Director, Thoracic Oncology Program  
Associate Program Director, Hematology/Medical Oncology  
Fellowship Program Lankenau Cancer



**Susan Gregory MD, FACP, FCCP**  
Medical Director, Critical Care  
Pulmonology Associates  
Lankenau Medical Center



**Gary Gilman, MD**  
Attending physician  
Internal Medicine at  
Lankenau Medical Center

**Register FREE of charge**

**[www.pathlms.com/patient-identification-in-NSCLC-webinar](http://www.pathlms.com/patient-identification-in-NSCLC-webinar)**

The American College of Chest Physicians ("CHEST") and its officers, regents, executive committee members, members, related entities, employees, representatives and other agents (collectively, "CHEST Parties") are not responsible in any capacity for, do not warrant and expressly disclaim all liability for, any content whatsoever in any CHEST publication or other product (in any medium) and the use or reliance on any such content, all such responsibility being solely that of the authors or the advertisers, as the case may be. By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any CHEST publication or other product. Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of CHEST Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages. This activity is not an official program of the American College of Chest Physicians (CHEST®).

**CHEST** Physician AstraZeneca

©2019 AstraZeneca.  
All rights reserved. US-34586 11/19



## Critical Care Commentary

## Nutrition support during adult critical illness

BY JAYSHIL J. PATEL MD;  
AND TODD RICE, MD, FCCP

**M**any critically ill patients you care for cannot maintain volitional oral intake. Therefore, nutrition support, through enteral or parenteral routes, remains a cornerstone in ensuring our critically ill patients receive substrates like glucose and protein. To understand the supportive role of nutrition during critical illness, let's identify and contextualize the different phases of critical illness.



Dr. Patel



Dr. Rice

mensal bacteria, epithelium, and the immune system, which maintains gut barrier functions, achieved, for example, by promoting tight junction protein production. Acute critical illness pathophysiology loosens epithelial tight junctions, and the gut barrier is breached, creating an opportunity for downstream migration of pancreatic enzymes and cytokines. Furthermore, the microbiome morphs into a virulent pathobiome, which induces gut-derived inflammation.

### When, where, and how much should we feed critically ill patients?

Since the acute phase of critical illness begins a series of events leading to negative energy balance and gut dysfunction, you might find early nutrition provision intuitive. Indeed, the 2016 ASPEN/SCCM and 2018 ESPEN critical care nutrition guidelines recommend early (within 24-48 hours of ICU admission) enteral nutrition (EN), delivered into the stomach, for all critically ill patients unable to maintain volitional intake. Meta-analyses of randomized controlled trials (RCT) conducted between 1979 and 2013 show early EN reduces both mortality and infectious complications, compared with no early nutrition (McClave SA et al. *JPEN*. 2016;40:159-211).

RCT level data do not show superiority of EN over parenteral nutrition (PN). Nonetheless, early EN is recommended over PN because it maintains epithelial barrier function and supports immunity.

What is the optimal nutrition dose? The 2016 ASPEN/SCCM guideline recommends getting to >80% estimated energy goal within 48-72 hours in patients with high nutrition risk while the 2018 ESPEN guideline suggests maintaining a hypocaloric, or not exceeding 70% of prescribed energy goal, during the early acute phase. The recommendation is based on meta-analyses of RCTs conducted between 2011 and 2017, which shows no mortality difference between hypocaloric and isocaloric nutrition.

Biologically plausible rationale for starting hypocaloric, as opposed to full dose nutrition, during the acute phase of critical illness includes: (a) the acute phase represents a period of hemodynamic instability and mitochondrial dysfunction, and full-dose EN may lead to feeding intolerance and lack of substrate utilization, respectively; (b) in those with risk factors (like pre-existing malnutrition), starting full dose nutrition may lead to refeeding syndrome; and (c) endogenous glucose production occurs during the acute phase, and full dose nutrition may worsen hyperglycemia.

Therefore, during the early acute phase of critical illness, hypocaloric feeding using an isosmotic formula, with a slow up-titration to goal rate thereafter, while monitoring for feeding intolerance and refeeding syndrome is a reasonable starting point.

### What is the role of parenteral nutrition in critical illness?

PN can be exclusive or supplemental (in a patient receiving EN). Historically, providers may have been reluctant to utilize PN for fear of infectious morbidity; however, contemporary pragmatic-design RCTs demonstrate safety with exclusive PN (Harvey SE et al. *N Engl J Med*. 2014;371:1673-84). When your patient has a contraindication for EN or does not tolerate it despite a trial of small bowel feeding, meta-analyses have shown a mortality benefit of early exclusive PN in malnourished patients, as compared with no nutrition (Braunschweig C et al. *Am J Clin Nutr*. 2001;74:534-42).

As for supplemental PN (SPN), the 2016 ASPEN/SCCM guideline does not recommend it until day 7 in all critically ill patients, while the 2018 ESPEN guideline recommends its use on a case-by-case basis. Since, two trials inform SPN use. The EAT-ICU trial showed no difference in 6-month physical function between EN group and early-goal-directed nutrition group, which included SPN to achieve estimated energy requirement during the first week of critical illness (Allingstrup MJ et al. *Intensive Care Med*. 2017;43:1637-47). The TOP-UP trial compared EN alone with EN plus SPN in nutritionally high risk patients (ie, those who stand to have more complications as a result of undernutrition) and

found those with a BMI < 25 kg/m<sup>2</sup> and those with a NUTRIC score >5 who received supplemental PN atop EN had improved 30-day mortality, as compared with EN alone (Wischmeyer P et al. *Crit Care*. 2017;21:142). Mortality was a secondary outcome, and further study of supplemental PN in nutritionally high-risk patients is warranted. Until further data are available, supplemental PN should probably be restricted during the acute phase of critical illness.

### Protein may be the important substrate

Proteolysis is the rule during critical illness, and amino acids are liberated from skeletal muscle breakdown. Using ultrasound, Puthuchery et al found a 17.7% reduction in rectus femoris cross-sectional area in 63 critically ill adults and identified muscle cellular infiltration at ICU day 10, suggesting critical illness leads to quantitative and qualitative muscle defects (Puthuchery Z et al. *JAMA*. 2013;15:1591-1600).

Since survivorship from critical illness is increasing, acquired loss of muscle mass may contribute to post-ICU physical functioning impairments. Thus, protein may be the most important substrate to deliver during critical illness. The 2016 ASPEN/SCCM guideline recommends 1.2 – 2.0 g/kg actual body weight (ABW)/day in nonobese critically ill patients.

Unfortunately, the optimal protein dose and the timing of intake are unknown. Observational studies suggest benefit with lower and higher doses, which creates equipoise for protein dose. The signal may be lost in heterogeneity, and observational data suggest higher protein dose may benefit patients with high nutritional risk. In terms of timing, one observational study found lower (<0.8 g/kg/d) protein dose before day 3 followed by higher (>0.8 g/kg/d) dose thereafter was associated with mortality benefit (Koekkoek WAC et al. *Clin Nutr*. 2019;38:883-890).

Until stronger data are available to guide optimal protein dose and timing, it is reasonable to observe the 2016 ASPEN/SCCM guideline protein recommendation of at least 1.2 g/kg/day. The 2018 ESPEN guideline recommends a similar dose of 1.3 g/kg/day.

NUTRITION // continued on page 31

### Phases of critical illness

The European Society of Parenteral and Enteral Nutrition's (ESPEN) 2018 critical care nutrition guideline incorporates stages of critical illness in making nutrition recommendations (Singer P et al. *Clin Nutr*. 2019;38:48-79). The first week of critical illness is the acute phase and hallmarked by catabolism and metabolic and hemodynamic instability. The late phase is thereafter and hallmarked by rehabilitation and anabolism or chronic critical illness. The acute phase is further divided into early (days 1-2) and late acute phase (days 3-7). The time-points are arbitrary and merely serve as placeholders. An objective marker to distinguish phases does not exist, and transition periods will be different for each patient.

### Acute phase

Critical illness defining conditions like circulatory shock, respiratory failure, and trauma are stressors and lead to two key acute phase perturbations that nutrition may have a role in altering:

The first is hypercatabolism. Critical illness defining conditions activate neuroendocrine, inflammatory/immune, adipokine, and GI tract hormone pathways that increase serum glucagon, cortisol, and catecholamines to promote glycogenolysis, gluconeogenesis, insulin resistance, protein catabolism, and restricted/impaired anabolism.

The second is gut dysfunction. During health, there is cross-talk signaling that occurs between com-



**This advertisement is  
not available for the digital edition.**



# News from the Board of Regents: Highlights of ongoing successes

BY NEIL FREEDMAN, MD, FCCP

CHEST leadership recently met for its fall quarterly face-to-face meeting prior to CHEST 2019 in New Orleans. Like all CHEST board meetings, the agenda was packed with important topics and a great deal of meaningful discussion. I left the meeting more energized about CHEST and its current and future offerings for our membership. Below are a few highlights from the meeting.

The meeting opened with an update from outgoing CHEST President Clayton Cowl, MD, MS, FCCP. He highlighted some of the organization's major achievements over the past year, including: Confirming and signing a new contract with our EVP/CEO Robert Musacchio, PhD; hiring a new Chief Learning Officer, a new Editor in Chief for the CHEST® journal, and a new Chief Legal Counsel; and expansion of the international strategy with CHEST Congress Bangkok and a CHEST

Regional meeting in Athens with plans for CHEST Congress 2020 in Bologna, Italy. In addition, CHEST convened a Digital Strategy Task Force, which made recommendations to improve how members, patients, and staff interact with our organization.

Dr. Musacchio reviewed some additional organizational accomplishments and areas of focus for the future. These included redefining the One CHEST operating model and a continued emphasis on international business development with plans for CHEST Congress 2020 in Italy, in addition to the exploration of future meetings in Singapore and the Philippines. CHEST remains dedicated to innovation by crafting new experiences for our members, including new games, virtual patient tours, and enduring activities and products. Many of these experiences were highlighted and on display at the recent CHEST annual meeting, including a pulmonary-focused

“escape room” and mobile “pop-up” simulation experiences. Kudos to CHEST 2019 Program Chair Bill Kelly, MD, FCCP, who led an incredible team of volunteer members in crafting the best collective member experience to date!



Dr. Freedman

Next up was a report out from the Governance Committee, which is composed of members of both the College Board of Regents (BOR) and Foundation Board of Trustees (BOT) and is responsible for the overall health of both boards and ensuring that the boards are consistently performing at a high level. Committee Chair, and CHEST Immediate Past President John Studdard, MD, FCCP, led the Committee presentation and discussion, which predominantly consisted of the delivery of slates for 2019-20 Board of Trustees (BOT) and Board of Regents (BOR) for Board approval. The new BOR-approved members are Douglas Arenberg, MD, FCCP; Sandhya Khurana, MD, FCCP; Lisa Moores, MD, FCCP; Michael Nelson, MD, FCCP; and Alexander Niven, MD, FCCP. Also, newly slated seats approved for the BOR: Ian Nathanson, MD, FCCP (CHEST Foundation President-Elect), and Angel Coz Yataco, MD, FCCP (Vice-Chair, Council of NetWorks).

New BOT-approved members are Roozehra Khan, DO, FCCP; Jill Popovich; and Burton Lesnick, MD, FCCP, with newly slated seats approved by the BOT that include Stephanie Levine, MD, FCCP (CHEST President); and Sai Haranath, MBBS, MPH, FCCP (Chair, Executive Committee of the Council of Global Governors).

In addition, David Schulman, MD, MPH, FCCP, and Robert De Marco, MD, FCCP, were elected as President-Designate of the BOR and BOT, respectively; both will serve their presidential terms beginning in October 2021.

Several others presented to the Board to review the past year's progress, future plans, and potential barriers to success:

- John Howington, MD, FCCP, Chair of the Finance Committee, updated the board on the financial health of the organization; in brief, CHEST had a very strong financial report for the past year based on strong expense management by our executive leadership team.

- The Council of Global Governors continues to see expansion in our international membership, though a potential ongoing barrier to future engagement will be developing an efficient mode of communication between the Global Governors and the international members they represent. Discussion around using the expertise within the Digital Strategy Task Force was offered as one method to improve international member communication and engagement.

- Alex Niven, MD, FCCP, Chair of the Education Committee, reported that they received an unprecedented 130 nominations for membership during this past election cycles and identified new members with exceptional credentials for the 2019-20 term. The Education Committee has expanded three of its subcommittees to better include and engage these individuals in ongoing education projects.

- Matt Miles, MD, FCCP, presented on behalf of the Training and Transitions Committee that continues to see increased engagement from trainees and training programs. This year's meeting in New Orleans had an increased number of trainee submissions, as well as a greater percentage of submissions that were accepted for presentation at the meeting. The committee will continue to evolve their strategy for engaging trainees and early career professionals.

- Christopher Hergott, MD, FCCP, Chair of the Membership Committee, reviewed several strategies and recommendations to expand our membership offerings and improve the value that we bring to our all of our members.

Finally, it was time to say thank you and farewell to our outgoing Board members. The following Board of Regents members were recognized for their many years of service to CHEST: Jack Buckley, MD, FCCP; John Studdard, MD, FCCP; David Zielinski, MD, FCCP; and Burt Lesnick, MD, FCCP.



With your help, the CHEST Foundation has spearheaded new endowments, created two new clinical research grants, and sponsored more young clinicians to attend CHEST Annual Meeting than ever before. None of this would be possible without your support.



**CHAMPION LUNG HEALTH TODAY**  
by making your year-end donation

[foundation.chestnet.org/donate/](http://foundation.chestnet.org/donate/)

As 2019 draws to a close, The CHEST Foundation would like to extend our sincere thanks to all of our donors. Through your support, we create positive change in the lives of patients across the globe.

*Wishing you all a happy holiday season!*

**THANK YOU**

# Mark J. Rosen, MD, Master FCCP Endowment

When most think of Mark J. Rosen, MD, Master FCCP, so many words come to mind: master educator, astute and caring clinician, researcher, mentor, leader. We recall his generosity, kindness, honesty, brilliance, and sense of humor.

Mark loved CHEST. He gave so much to the organization and was happy to do so. He was one of the rare Past Presidents who contributed even more after his presidency than during or before. Mark left an enormous footprint on CHEST's educational programs, including the CHEST Annual Meeting, Pulmonary Board Review, and SEEK. He was instrumental in building our international educational programs and a key player in empowering our Chinese colleagues in establishing pulmonary fellowships in their country. Much of what we have all accomplished at CHEST and in pulmonary medicine is directly related to the wonderful mentors we have had in the organization, and Mark was certainly one of the most prominent.

Mark introduced many of us to so many friends and mentors. He especially did this for hundreds of trainees and junior faculty throughout his career. What made him most happy was seeing his trainees and mentees succeed – Mark was THE example of an outstanding mentor. After his passing, and in recognition



Dr. Mark J. Rosen

of his work that can and will live on, the CHEST Foundation has established an endowment with a major focus that truly honors Mark's most memorable traits – the Rosen International Scholarship Fund.

Mark always believed the core strength of the college was education. The CHEST Foundation is endowing the Rosen International Scholarship and raising \$100,000 to support deserving international clinicians. This endowed fund will directly support international CHEST members' travel to the CHEST Annual Meeting affording CHEST's world-class educational and mentorship opportunities to members who could not otherwise attend.

To support the Mark J. Rosen, MD, Master FCCP Endowment, his legacy, and international CHEST members, visit <https://tinyurl.com/wf7zeq6>.

## Nutrition // continued from page 28

### Future research and summary

Many questions remain unanswered and present opportunities for future research. Priorities for critical care nutrition research include studying the impact of combined nutrition and exercise in the acute and late phases of critical illness and identifying best tools to differentiate responses to caloric and protein intake.

In summary, critical illness has acute and late phases. The acute phase is a hypercatabolic state leading to negative energy and nitrogen balance and gut dysfunction. Take-home points for nutrition support in the acute phase of critical illness are:

1. It is reasonable to start early hypocaloric EN with an isosmotic formula with slow up-titration over the first week of critical illness while

monitoring for refeeding syndrome and feeding intolerance.

2. Use exclusive PN in ICU patients with pre-existing malnutrition when EN is contraindicated or not tolerated.

3. Supplemental PN should probably be restricted during the acute phase of critical illness.

4. Optimal protein dose and timing are unknown. It is reasonable to start with at least 1.2 g/kg ABW/day in non-obese patients.

*Dr. Patel is with the Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.*

*Dr. Rice is with the Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Vanderbilt University, Nashville, Tennessee.*

REGISTRATION NOW OPEN!

## 2020 COURSES

CHEST Global Headquarters  
Glenview, IL



## CHEST Education Calendar

FEBRUARY 20-22

Comprehensive Bronchoscopy  
With EBUS

FEBRUARY 27-29

Mechanical Ventilation: Advanced  
Critical Care Management

MARCH 5-7

Ultrasonography: Essentials  
in Critical Care

MARCH 20-21

Bronchoscopy and Chest Tubes  
in the ICU

MARCH 27-28

Advanced Clinical Training  
in Pulmonary Function Testing

APRIL 30-MAY 2

Critical Skills for Critical Care:  
A State-of-the-Art Update and  
Procedures for ICU Providers

MAY 29-30

Therapeutic Bronchoscopy  
for Airway Obstruction

JUNE 4-6

Advanced Critical Care Echocardiography

JUNE 11-13

Difficult Airway Management

JULY 23-25

Mechanical Ventilation: Advanced  
Critical Care Management

AUGUST 6-8

Cardiopulmonary Exercise Testing

SEPTEMBER 10-12

Difficult Airway Management

SEPTEMBER 17-19

Ultrasonography: Essentials  
in Critical Care

SEPTEMBER 24-26

Comprehensive Bronchoscopy  
With EBUS

NOVEMBER 5-7

Extracorporeal Support for Respiratory  
and Cardiac Failure in Adults

NOVEMBER 12-14

Critical Care Ultrasound:  
Integration Into Clinical Practice

NOVEMBER 19-20

Comprehensive Pleural Procedures

NOVEMBER 21

NEW! Advanced Airway  
Management with Cadavers

DECEMBER 3-5

Ultrasonography: Essentials  
in Critical Care

DECEMBER 11-12

Advanced Critical Care Echocardiography  
Board Review Exam Course

 CHEST®

Calendar subject to change. For most  
current course list and more information,  
visit [livelearning.chestnet.org](http://livelearning.chestnet.org).

Register today  
[chestnet.org/livelearning](http://chestnet.org/livelearning)



# NAMDRC legislative initiatives take shape

BY PHIL PORTE

Executive Director, NAMDRC

Two priorities of NAMDRC have moved into the formal congressional arena. The issues focus on access to pulmonary rehabilitation and CMS's move to include home mechanical ventilation in competitive bidding.

**Pulmonary Rehabilitation – The Problem:** One of the major concerns to CMS and Congress is the fact that different payment methodologies for the same service result in different payment amounts dependent upon the actual site of service. To address the phenomenon of hospitals purchasing certain physician practices to game the payment system, Congress included in the 2015 Budget Act a provision that would remove incentives for such hospital purchases by stating that new hospital outpatient services must be within 250 yards of the main hospital campus in order to receive payment based on the hospital outpatient prospective payment system methodology. If a hospital opens such services beyond that 250-yard threshold, the hospital would be reimbursed at the physician fee schedule amount for the same service. Likewise, if an off campus program moved its grandfathered location because of expansion, loss of lease, etc, the physician fee schedule would again kick in.

For pulmonary rehabilitation services, this is extremely problematic and is tying the hands of hospitals providing this service. The physician fee schedule payment for pulmonary rehabilitation is less than \$30 for 1 hour of service, and it is, therefore, not surprising that the service is simply not provided in physician offices. In fact, Medicare data show that all physician specialties bill less than \$1M for code G0424, and we believe that most of that is likely billing error. Pulmon-

ologists bill less than \$500K for code G0424, and putting that number in context, the entire Medicare program is approaching \$700B in outlays.

**Pulmonary Rehabilitation – The Solution:** As a solution to this problem, HR 4838 has been introduced in the House of Representatives. There is no specific reference to pulmonary rehabilitation in the bill as our approach is based not only on substance but political considerations, as well. Using CMS' own acknowledgment of "unintended consequences," this legislation would exempt all CPT® codes from the restrictions imposed by Section 603 of the 2015 Budget Act when the physician billings for that code are under \$2M for the most recent year for which data are



Mr. Porte

available. CMS has signaled to us that such a limitation would apply only to pulmonary and cardiac rehab services, but others may be affected, as well. By putting a dollar limit rather than identifying a specific service for such a "carve out," it is a more politically viable approach.

Bills such as this rarely see the light of day; however, such provisions are often attached to larger, more substantive bills. For nearly 2 decades, the common legislative vehicle for such provisions is a larger Medicare bill, often including "must pass Medicare extender" provisions that are slated to expire on a particular date. Our goal is to include HR 4838 in such a package of extenders some time between now and the end of this Congress in 2020.

**Home Mechanical Ventilation – The Problem:** CMS has proposed inclusion of home mechani-

cal ventilation in competitive bidding for durable medical equipment. Such a regulatory proposal is fraught with downside risk, most notably that such a policy would follow the history of liquid oxygen. Liquid O2 has virtually disappeared from the marketplace since it was included in competitive bidding as suppliers simply refused to provide liquid oxygen systems as their own bidding dropped the price to prohibitively low levels. Also, because there is a statutory requirement that such payment be made on the basis of "frequent and substantial servicing," and that stipulation could trigger wide variations in actual bidding because some states require involvement of respiratory therapists in such services, while others do not.

It is critical to understand that the driving force behind all of this is the reality that CMS' own coverage policies for home mechanical ventilation are seriously flawed and outdated, creating perverse incentives for physicians to order easily accessible systems rather than clinically appropriate ones. NAMDRC and its sister societies have been pushing CMS to revise those policies with no success.

**Home Mechanical Ventilation – The Solution:** Our solution is twofold. HR 4945 bill was introduced on November 1, 2019. First, the proposed legislation would create a blanket exemption for home mechanical ventilation from competitive bidding. Second, it requires CMS to convene a technical expert panel to craft up-to-date policies for home mechanical ventilation.

The political strategy here is slightly different. While passage of the bill is certainly our first choice, we believe that introduction of the bill is a red flag signal to CMS for the need to revise its coverage policies as those policies are the root cause of the growth of home mechanical ventilation outlays.

## This month in the journal CHEST®

### Editor's Picks

BY PETER J. MAZZONE, MD, MPH, FCCP

Editor in Chief

### Editorials

**Pulmonary Embolism Cardiac Arrest: Thrombolysis During Cardiopulmonary Resuscitation and Improved Survival.**

By Drs. B. W. Bottiger and W. A. Wetsch.

**Interstitial Lung Abnormalities: A Word of Caution.**

By Drs. V. Tzilas and D. Bouros.

### Original Research

**Thrombolysis During Resuscita-**

**tion for Out-of-Hospital Cardiac Arrest Caused by Pulmonary Embolism Increases 30-Day Survival: Findings From the French National Cardiac Arrest Registry.**

By Dr. F. Javaudin, et al.

**Interstitial Lung Abnormalities and Lung Cancer Risk in the National Lung Screening Trial.**

By Dr. S-A. Whittaker Brown, et al.

### Commentary

**Publishing a Clinical Research Manuscript: Guidance for Early-Career Researchers With a Focus on Pulmonary and Critical Care Medicine.**

By Dr. E. M. Viglianti, et al.

## CHEST 2020 honor lectures and award nominations

Each year, CHEST honors physicians and others who are making significant or meritorious contributions to chest medicine. All honorees are recognized for advancing work in specific areas of chest medicine, mentorship, and training, furthering the work of CHEST, and more.

If you believe you have a colleague who should be recognized

for their distinguished work, please submit a nomination. Those selected for an annual award and honor lecture will be featured at CHEST 2020 in Chicago.

Deadline: Monday, January 6, 2020

Questions? Please contact Emily Petraglia, Manager, Volunteer Engagement by email: epetraglia@chestnet.org.

### INDEX OF ADVERTISERS

<b>Biodesix</b> Nodify XL2	29	<b>Genentech USA, Inc.</b> Esbriet	2-5
<b>Biomerieux</b> BioFire	36	<b>GSK</b> Nucala	18-21, 33
<b>Boehringer Ingelheim Inc.</b> Corporate	13	<b>Mylan Specialty L.P.</b> Yupelri	25-26
<b>Boston Scientific Corporation</b> EKOS	23	<b>Novartis</b> Corporate	11
		<b>Paratek Pharmaceuticals, Inc.</b> Nuzyra	15-17

**This advertisement is  
not available for the digital edition.**



## PULMONARY PERSPECTIVES®

# An update on the current standard for ultrasound education in fellowship

BY LEWIS SATTERWHITE, MD, FCCP; KALEB VEIT, DO; AND ARIEL SHILOH, MD, FCCP

Point-of-care ultrasound (POCUS) is an essential part of ICU care. It has been demonstrated to improve patient safety and outcomes through procedural guidance (Brass P, et al. *Cochrane Database Syst Rev.* 2015 Jan 9;1:CD006962) and aid in accurate and timely diagnosis of cardiopulmonary failure (Lichtenstein DA, Mezière GA. *Chest.* 2008 Jul;134[1]:117-25). Due in part to increasing affordability and portability of ultrasound technologies, the use of POCUS has become seemingly ubiquitous and will continue to increase in coming years. According to expert groups representing 12 critical care societies worldwide, general critical care ultrasound and basic critical care echocardiography should be mandatory training for ICU physicians (Expert Round Table on Ultrasound

in ICU. *Intensive Care Med.* 2011 Jul;37[7]:1077-83).

Currently, POCUS is not universally taught to pulmonary and critical care fellows (PCCM); and when training does exist, curriculums are not standardized. This is in part due to the broadly worded requirements set forth from the ACGME for pulmonary disease and critical care medicine. The totality of ACGME common program requirements as it regards to ultrasound training are as follows: 1. “Fellows must demonstrate competence in procedural and technical skills, including ... use of ultrasound techniques to perform thoracentesis and place intravascular and intracavitary tubes and catheters”; and 2. “Fellows must demonstrate knowledge of imaging techniques commonly employed in the evaluation of patients with pulmonary disease or critical illness, including the use of ultrasound” (*ACGME Program Requirements for Graduate Medical Education in Pulmonary Disease and*

*Critical Care Medicine*).

In comparison, recently updated ACGME common program requirements for ultrasound in emergency medicine and anesthesiology residencies are robust and detailed. Requirements for anesthesia residency training include: “... competency in using surface ultrasound ... and transthoracic echocardiography to guide the performance of invasive procedures and to evaluate organ function and pathology ... understanding the principles of ultrasound, including the physics of ultrasound transmission, ultrasound transducer construction, and transducer selection for specific applications, to include being able to obtain images with an understanding of limitations and artifacts ... obtaining standard views of the heart and inferior vena cava with transthoracic echocardiography allowing the evaluation of myocardial function, estimation of central venous pressure, and gross pericardial/cardiac pathology (eg,

large pericardial effusion) ... using transthoracic ultrasound for the detection of pneumothorax and pleural effusion ... using surface ultrasound to guide vascular access (both central and peripheral) ... describing techniques, views, and findings in standard language” (*ACGME Program Requirements for Graduate Medical Education In Anesthesiology*).

Herein lies a stark contrast in what is required of programs that train physicians to care for unstable patients and the critically ill. Current requirements leave graduates of PCCM training programs vulnerable to completing ACGME milestones without being adequately prepared to evaluate patients in a modern ICU setting. Hospitals credentialing committees expect PCCM graduates to be suitably trained in ultrasound. Regrettably, there is no assurance that is true, or standardized, with current PCCM fellowship training requirements.

There is not a national standard for



## NEW! CHEST SEEK™ Pulmonary Medicine: 29th Edition

The latest SEEK study product straight from the pulmonary medicine board subspecialty examination content blueprints is now available.

- Study for board and accreditation exams.
- Review at your convenience.
- Earn CME credit and MOC points.

Use CHEST SEEK resources to test and improve your clinical skills in recall, interpretation, and problem-solving. Case-based questions reflect the content of the board certification examinations. Available in print or via the CHEST SEEK Library subscription.



Print | <http://bit.ly/SEEKPulm29>  
CHEST SEEK Library | [seeklibrary.chestnet.org](http://seeklibrary.chestnet.org)



CHEST®  
Congress  
2020

Bologna  
Italy | 25-27 June



## Join us in ITALY

Join colleagues from around the world and gain access to the CHEST learning and training experience at our congress. This unique program will go beyond the classroom style setting to connect you to leading experts who will teach and help you and your team develop your skills.

**CHEST Congress 2020 Italy will be chaired by**

William F. Kelly, MD, FCCP  
Girolamo Pelaia, MD, FCCP

[Register at congress.chestnet.org](http://congress.chestnet.org)



competency assessment or requirements for credentialing in POCUS for critical care physicians at this time. However, multiple national and international critical care societies, including CHEST, have consensus statements and recommendations outlining the areas of competence expected in critical care ultrasound (Mayo PH, et al. *CHEST*. 2009 Apr;135[4]:1050-60, Expert Round Table on Ultrasound in ICU. *Intensive Care Med*. 2011 Jul;37(7):1077-83). The PCCM ACGME requirements should be updated to reflect such recommendations, thereby placing greater emphasis on ultrasound teaching requirements and standardized curriculums. Despite the current ACGME program requirements, it is incumbent upon critical care training programs to provide competency-based education of this now “standard of care” technology.

Barriers to universal POCUS training exist. Fellowship programs may lack trained, ultrasound confident faculty, time, and funding to successfully develop and sustain an ultrasound curriculum (Eisen LA, et al. *Crit Care Med*. 2010;38[10]:1978-83; Patrawalla P, et al. *J Intensive Care Med*. 2019 Feb 12:[Epub ahead of print]).

Although access to adequate quality and quantity of ultrasound machines is less often a problem than in the past, many institutions lack archival and image review software that allows for quality assurance of image acquisition, and some still may not have a faculty member with expertise and ability to champion the cause.

In attempts to mitigate the local faculty gaps, national and regional solutions have been developed for ultrasonography education. CHEST has educated more than 1,400 learners in the Ultrasound Essentials course since 2013. Also, grassroots efforts have led to the development of courses specifically designed to teach incoming PCCM fellows. Using a collaborative and cost-effective model, these regional programs pool faculty and experts in the field to train multiple fellowship programs simultaneously. The first of these was created over a decade ago in New York City (Patrawalla P, et al. *J Intensive Care Med*. 2019 Feb 12:[Epub ahead of print].)

Currently, there are at least four regional annual ultrasound courses directed at teaching PCCM fellows. These courses are typically held over multiple days and encompass the basics of critical care ultrasound, including vascular, thoracic, ab-

dominal, cardiac, and procedural imaging. By estimation, these four courses provide a basic ultrasonography education to approximately two-thirds of first year pulmonary and critical care fellows in the United States. In addition to training fellows, these programs also serve as a platform for the development of local faculty experts, so that training can continue at their institutions.

Introductory courses are highly effective (Dinh VA, et al. *Crit Care Res Pract*. 2015 Aug 5:675041; Patrawalla P, et al. *J Intensive Care Med*. 2019 Feb 12: [Epub ahead of print]), but ongoing education, assessment, and quality assurance is required to achieve sustained competence. Ideally, training in POCUS should entail a dedicated, intensive introduction to the competencies of critical care ultrasound (such as the above regional courses or CHEST ultrasound courses), followed by a formal curriculum within the PCCM fellowship programs.

This curriculum should afford the trainee exposure to critically ill patients in an environment with adequate ultrasound equipment and a method to record studies. The trainee then interprets the acquired studies in clinical context. Preferably, the program will afford the trainee real-time quality assurance for image acquisition and interpretation by a program champion. Quality assurance can be provided on site or remotely using fixed interval review sessions.

Lastly, the program should have internal milestones to evaluate when a trainee has reached competency to perform these tasks independently. The completion of training should include a letter to any future employer attesting to the trainee’s acquisition of these skills and ability to apply them safely while caring for the critically ill. This robust education is occurring in many centers across the country. PCCM fellowship programs owe it to their trainees, and patients, that competency-based critical care ultrasound training is robust, standardized, and supported.

*Dr. Satterwhite is Associate Professor of Medicine, Medical Director, Medical ICU, University of Kansas School of Medicine; Dr. Veit is a Pulmonary and Critical Care Fellow, University of Kansas School of Medicine, Kansas City, Kansas; and Dr. Shiloh is Associate Professor of Medicine, Director, Critical Care Consult Service, Albert Einstein College of Medicine, New York, NY.*



## Comprehensive Bronchoscopy With Endobronchial Ultrasound February 20-22

Join us for the first hands-on, interactive CHEST Live Learning course of 2020: Comprehensive Bronchoscopy With Endobronchial Ultrasound.

Learn new skills and refresh your knowledge from experts in bronchoscopy and procedure-related training. Attend and acquire essential and advanced diagnostic bronchoscopy techniques, including EBUS-TBNA specimen handling and processing.

REGISTER TODAY

[bit.ly/CompBronchFeb2020](https://bit.ly/CompBronchFeb2020)



**This advertisement is  
not available for the digital edition.**

